

2021 Medicines in Development: Health Equity

Alzheimer's Disease

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
AAT-009 (5-HT4 partial agonist)	AskAt Nagoya, Japan	Alzheimer's disease	Phase I completed www.askat-inc.com
ABBV-8E12 (anti-tau antibody)	AbbVie North Chicago, IL	Alzheimer's disease	Phase II www.abbvie.com
ACI-35.030 (anti-pTau vaccine)	AC Immune Lausanne, Switzerland Janssen Research & Development Raritan, NJ	mild to moderate Alzheimer's disease	Phase II www.acimmune.com www.janssen.com
AD-35 (amyloid-beta aggregation inhibitor)	Hisun USA Bridgewater, NJ	Alzheimer's disease	Phase II www.hisunusa.com
Adlarity donepezil transdermal patch	Corium International Menlo Park, CA	Alzheimer's disease	application submitted www.coriumgroup.com
AGB101 (levetiracetam low-dose)	AgenBio Baltimore, MD	mild cognitive impairment in Alzheimer's disease	Phase III www.agenebio.com
AKST/GRF6019/6021 (neurogenesis stimulant)	Alkahest San Carlos, CA	mild to moderate Alzheimer's disease	Phase II www.alkahest.com

Alzheimer's Disease

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
AL002 (TREM2 protein stimulant)	AbbVie North Chicago, IL Alector South San Francisco, CA	early Alzheimer's disease	Phase II www.abbvie.com www.alector.com
AL003 (SIGLEC 3)	AbbVie North Chicago, IL Alector South San Francisco, CA	Alzheimer's disease	Phase I www.abbvie.com www.alector.com
ALX-001 (mGluR5 modulator)	Allyx Therapeutics New Haven, CT	Alzheimer's disease	Phase I www.allyxthera.com
ALZ-801 (amyloid beta-protein inhibitor)	Alzheon Framingham, MA	early Alzheimer's disease (APOE4/4 homozygotes) (Fast Track)	Phase III www.alzheon.com
		early Alzheimer's disease (APOE4 carriers)	Phase II www.alzheon.com
ALZT-OP1 (amyloid beta-protein inhibitor/ inflammation mediator inhibitor)	AZTherapies Boston, MA	Alzheimer's disease	Phase III www.aztherapies.com
AMX0035 (sodium phenylbutyrate/ tauroursodeoxycholic acid)	Amylyx Pharmaceuticals Cambridge, MA	Alzheimer's disease	Phase II www.amylyx.com

Alzheimer's Disease

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ANAVEX®2-73 (blarcamesine) (M1 muscarinic receptor agonist/ intracellular sigma 1 receptor agonist)	Anavex Life Sciences New York, NY	Alzheimer's disease	Phase II/III www.anavex.com
ANVS301 (bisnorcymserine)	Annovis Bio Berwyn, PA	advanced Alzheimer's disease	Phase I www.annovisbio.com
ANVS401 (R-phenserine)	Annovis Bio Berwyn, PA	Alzheimer's disease	Phase II www.annovisbio.com
		Alzheimer's disease in Down syndrome	Phase I www.annovisbio.com
AR1001 (PDE5 inhibitor)	AriBio San Diego, CA	Alzheimer's disease	Phase II www.aribiousa.com
AstroStem® mesenchymal stem cell therapy	Nature Cell Seoul, South Korea	Alzheimer's disease	Phase I/II completed www.naturecell.co.kr
ATH-1017 (HGF stimulant)	Athira Pharma Bothell, WA	Alzheimer's disease	Phase II www.athira.com
atuzaginstat (COR388) (lysine gingipain inhibitor)	Cortexyme South San Francisco, CA	Alzheimer's disease	Phase III www.cortexyme.com

Alzheimer's Disease

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
AUS-131 (nonhormonal estrogen receptor agonist)	Ausio Pharmaceuticals Cincinnati, OH University of Kansas Kansas City, KS	Alzheimer's disease	Phase I/II www.ausiopharma.com
AVP-786 (dextromethorphan analogue/ultra-low dose quinidine)	Avanir Pharmaceuticals Aliso Viejo, CA	agitation in Alzheimer's disease (Fast Track)	Phase III www.avanir.com
AXS-05 (bupropion/dextromethorphan)	Axsome Therapeutics New York, NY	agitation in Alzheimer's disease (Fast Track)	Phase III www.axsome.com
BAN2401 (Iecanemab) (anti-amyloid beta mAb)	Biogen Cambridge, MA Eisai Woodcliff Lake, NJ	early Alzheimer's disease, preclinical Alzheimer's disease	Phase III www.biogen.com www.eisai.com
beptranemab (UCB0107) (Tau protein inhibitor)	UCB Smyrna, GA	Alzheimer's disease	Phase II www.ucb.com
BIIB076 (anti-tau mAb)	Biogen Cambridge, MA	Alzheimer's disease	Phase I www.biogen.com
BIIB080 (IONIS-MAPT _{RX}) (tau-targeting protein)	Biogen Cambridge, MA Ionis Pharmaceuticals Carlsbad, CA	mild Alzheimer's disease	Phase I www.biogen.com www.ionispharma.com

Alzheimer's Disease

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
BIIB092 (gosuranemab) (anti-extracellular tau antibody)	Biogen Cambridge, MA	Alzheimer's disease	Phase II www.biogen.com
BNC375 (positive allosteric modulator)	Merck Kenilworth, NJ Bionomics Thebarton, Australia	cognitive dysfunction in Alzheimer's disease	Phase I www.merck.com www.bionomics.com.au
BPN14770 (zatolmilast) (PDE4D inhibitor)	Tetra Discovery Partners Grand Rapids, MI Shionogi Florham Park, NJ	Alzheimer's disease	Phase II www.tetradiscovery.com www.shionogi.com
bryostatin 1 (protein kinase C stimulant)	Synaptogenix New York, NY	Alzheimer's disease	Phase II www.synaptogen.com
crenezumab (anti-amyloid beta antibody)	Roche/Genentech South San Francisco, CA	familial Alzheimer's disease in healthy people	Phase II www.gene.com
CT1812 (amyloid beta oligomer receptor antagonist)	Cognition Therapeutics Pittsburgh, PA	mild to moderate Alzheimer's disease (Fast Track)	Phase II www.cogrx.com
		early Alzheimer's disease	Phase I www.cogrx.com
CY6463 (sGC stimulant)	Cyclerion Therapeutics Cambridge, MA	Alzheimer's disease with vascular pathology	Phase I www.cyclerion.com

Alzheimer's Disease

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
donanemab (LY3002813) (N3pG-amyloid beta antibody)	Lilly Indianapolis, IN	Alzheimer's disease	Phase III www.lilly.com
E2006 (orexin receptor antagonist)	Eisai Woodcliff Lake, NJ	Alzheimer's disease dementia	Phase II www.eisai.com
E2511 (neuron stimulant)	Eisai Woodcliff Lake, NJ	Alzheimer's disease	Phase I www.eisai.com
E2814 (Tau protein inhibitor)	Eisai Woodcliff Lake, NJ	Alzheimer's disease	Phase I www.eisai.com
gantenerumab (RG1450) (amyloid beta-protein inhibitor)	Roche/Genentech South San Francisco, CA	Alzheimer's disease	Phase III www.gene.com
HB-adMSCs (autologous adipose-derived mesenchymal stem cell therapy)	Hope Biosciences Sugar Land, TX	Alzheimer's disease	Phase I/II www.hope.bio
IGC-AD1 (phytocannabinoid therapeutic)	IGC Pharma Potomac, MD	Alzheimer's disease	Phase I www.igcpharma.com
JNJ-63733657 (phospho-tau mAb inhibitor)	Janssen Research & Development Raritan, NJ	early Alzheimer's disease	Phase II www.janssen.com

Alzheimer's Disease

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
JOT107 (oral capsule of trans-resveratrol)	Jupiter Orphan Therapeutics Jupiter, FL	Alzheimer's disease	Phase I www.jupiterorphan.com
LM11A-31 (p75 neurotrophin receptor)	Pharmatrophix Menlo Park, CA	mild to moderate Alzheimer's disease	Phase I/II completed www.pharmatrophix.com
LMTX (tau protein aggregation inhibitor/ TDP-43 aggregation inhibitor)	TauRx Pharmaceuticals Singapore	mild to moderate Alzheimer's disease	Phase III www.taurx.com
Lu AF87908 (Tau protein inhibitor)	Lundbeck Deerfield, IL	Alzheimer's disease	Phase I www.lundbeck.com
LX1001 (AAV-mediated gene therapy)	LEXEO Therapeutics New York, NY	APOE4-associated Alzheimer's disease (Fast Track)	Phase I www.lexeotx.com
LY3372689 (O-GlcNAcase inhibitor)	Lilly Indianapolis, IN	Alzheimer's disease	Phase I www.lilly.com
LY3372993 (N3pG-Ab mAb)	Lilly Indianapolis, IN	Alzheimer's disease	Phase I www.lilly.com
LYN-157 (donepezil/memantine ER)	Lyndra Therapeutics Watertown, MA	Alzheimer's disease	Phase I www.lyndra.com

Alzheimer's Disease

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
MEDI1814 (anti-amyloid beta 42 mAb)	AstraZeneca Wilmington, DE	Alzheimer's disease	Phase I www.astrazeneca.com
mesenchymal stem cell therapy (autologous adipose-derived)	Celltex Therapeutics Houston, TX	Alzheimer's disease	in clinical trials www.celltexbank.com
mesenchymal stem cell therapy (allogeneic bone marrow-derived)	Longeveron Miami, FL	Alzheimer's disease	Phase I www.longeveron.com
mesenchymal stem cell therapy (ischemic-tolerant stem cells)	Stemedica Cell Technologies San Diego, CA	Alzheimer's disease	Phase II www.stemedica.com
MK-1942	Merck Whitehouse Station, NJ	Alzheimer's disease (+donepezil)	Phase I www.merck.com
NA-831 (traneurocin) (neurogenesis stimulant)	NeuroActiva San Jose, CA	Alzheimer's disease	Phase II www.neuroactiva.com
NE3107 (NF-κB/ERK1/2/MAPK3/1 inhibitor)	NeurMedix San Diego, CA	Alzheimer's disease	Phase III www.neurmedixinc.com
neflamapimod (VX-745) (p38 mitogen-activated protein kinase inhibitor)	EIP Pharma Cambridge, MA	Alzheimer's disease	Phase II www.eippharma.com

Alzheimer's Disease

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
NLY01-AD (GLP-1R agonist)	Neuraly Gaithersburg, MD	Alzheimer's disease	Phase II www.neuraly.com
NNI-362 (neuron regenerative therapy)	Neuronascent Clarksville, MD	Alzheimer's disease	Phase I www.neuronascent.com
NTRX-07 (cannabinoid receptor CB2 agonist)	NeuroTherapia Gates Mills, OH	Alzheimer's disease	Phase I www.neurotherapia.com
Nuplazid® pimavanserin	ACADIA Pharmaceuticals San Diego, CA	psychosis and agitation in Alzheimer's disease	Phase II completed www.acadia-pharm.com
pepinemab (anti-SEMA4D mAb)	Vaccinex Rochester, NY	Alzheimer's disease	Phase I/II www.vaccinex.com
PQ912 (QC inhibitor)	Vivoryon Therapeutics Halle, Germany	early Alzheimer's disease	Phase II www.vivoryon.com
PU-AD (icapamespib) (HSP90 heat-shock protein inhibitor)	Samus Therapeutics Topsfield, MA	Alzheimer's disease	Phase II www.samustherapeutics.com
Rexulti® brexpiprazole	Lundbeck Deerfield, IL Otsuka Pharmaceutical Tokyo, Japan	agitation in Alzheimer's disease (Fast Track)	Phase III www.lundbeck.com www.otsuka.com

Alzheimer's Disease

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
RG6102 (brain shuttle gantenerumab)	Roche/Genentech South San Francisco, CA	Alzheimer's disease	Phase II www.roche.com
semaglutide oral (GLP-1 receptor agonist)	Novo Nordisk Plainsboro, NJ	early Alzheimer's disease	Phase III www.novonordisk.com
semorinemab (RG6100) (tau protein inhibitor)	AC Immune Lausanne, Switzerland Roche/Genentech South San Francisco, CA	Alzheimer's disease	Phase I www.roche.com
SEP-380135	Sunovion Marlborough, MA	agitation in Alzheimer's disease	Phase I www.sunovion.com
simufilam (microfilament protein modulator)	Cassava Sciences Austin, TX	Alzheimer's disease	Phase II www.cassavasciences.com
SNK01 (autologous NK cell therapy)	NKGen Biotech Santa Ana, CA	Alzheimer's disease	Phase I www.nkgenbiotech.com
solanezumab (amyloid beta protein inhibitor)	Lilly Indianapolis, IN	preclinical Alzheimer's disease	Phase III www.lilly.com
SUVN-502 (masupirdine) (serotonin 6 receptor antagonist)	Suven Life Sciences Hyderabad, India	moderate Alzheimer's disease (adjunctive treatment)	Phase II completed www.suven.com

Alzheimer's Disease

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
T-817MA (edoneric) (amyloid beta-protein inhibitor)	Toyama Chemical Tokyo, Japan	Alzheimer's disease	Phase II www.toyama-chemical.co.jp
T3D-959 (PPAR-delta/gamma agonist)	T3D Therapeutics Research Triangle Park, NC	Alzheimer's disease	Phase II www.t3dtherapeutics.com
troriluzole (BHV-4157) (glutamate modulator)	Biohaven Pharmaceuticals New Haven, CT	Alzheimer's disease	Phase II www.biohavenpharma.com
UB-311 (anti-amyloid endobody vaccine)	Vaxxinity Dallas, TX	Alzheimer's disease	Phase II www.vaxxinity.com
UE-2343 (11 β -HSD1 inhibitor)	Actinogen Medical Sydney, Australia	dementia in Alzheimer's disease	Phase II www.actinogen.com
vafidemstat (LSD1/MAOB inhibitor)	Oryzon Genomics Cambridge, MA	Alzheimer's disease	Phase II completed www.oryzon.com
XPro1595 (TNF inhibitor)	INmune Bio La Jolla, CA	Alzheimer's disease	Phase I www.inmune.com
zagotenemab (LY3303560) (tau deposit antibody)	Lilly Indianapolis, IN	Alzheimer's disease	Phase II www.lilly.com

Asthma <u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
ADX-629 (aldehyde inhibitor)	Aldeyra Therapeutics Lexington, MA	allergic asthma	Phase II www.aldeyra.com
AirDuo RespiClick® salmeterol/fluticasone propionate	Teva Branded Pharmaceutical Products Parsippany, NJ	asthma (4-11 years old)	Phase III completed www.tevapharm.com
APC-1000 (beclomethasone MDI)	Adamis Pharmaceuticals San Diego, CA	asthma	Phase II www.adamispharmaceuticals.com
APC-4000 (fluticasone MDI)	Adamis Pharmaceuticals San Diego, CA	asthma	Phase II www.adamispharmaceuticals.com
ArmonAir™ RespiClick® fluticasone propionate inhalation	Teva Branded Pharmaceutical Products Parsippany, NJ	asthma (4-11 years old)	Phase III completed www.tevapharm.com
AZD0449 (JAK inhibitor)	AstraZeneca Wilmington, DE Rigel Pharmaceuticals South San Francisco, CA	chronic asthma	Phase I www.astrazeneca.com www.rigel.com
AZD1402 (PRS-060) (IL-4Ra antagonist)	AstraZeneca Wilmington, DE Pieris Pharmaceuticals Boston, MA	asthma	Phase II www.astrazeneca.com www.pieris.com
Breztri Aerosphere™ budesonide/glycopyrrolate/ formoterol fumarate	AstraZeneca Wilmington, DE	asthma	Phase III www.astrazeneca.com

Asthma Product Name	Sponsor	Indication	Development Status
CBP-201 (IL-4 alpha receptor antagonist)	Connect Biopharma San Diego, CA	asthma	Phase II www.connectbiopharm.com
CHF5993 (beclomethasone/formoterol/ glycopyrrolate)	Chiesi USA Cary, NC	asthma	Phase II www.chiesiusa.com
CSJ117 (TSLP inhibitor)	Novartis Pharmaceuticals East Hanover, NJ	severe asthma	Phase II www.novartis.com
dexpramipexole (selective dopamine receptor agonist)	Knopp Biosciences Pittsburgh, PA	eosinophilic asthma	Phase II www.knoppbio.com
Dupixent [®] dupilumab	Sanofi Bridgewater, NJ Regeneron Tarrytown, NY	asthma (6-11 years old)	application submitted www.sanofi.com www.regeneron.com
Fasenra [®] benralizumab	AstraZeneca Wilmington, DE	severe uncontrolled asthma	Phase III www.astrazeneca.com
GB001 (DP2 antagonist)	Gossamer Bio San Diego, CA	asthma	Phase II www.gossamerbio.com
GBR 310 (omalizumab biosimilar)	Glenmark Pharmaceuticals Mahwah, NJ	allergic asthma	Phase II www.glenmarkpharma-us.com

Asthma Product Name	Sponsor	Indication	Development Status
GSK3511294 (depemokimab) (IL5 long-acting mAb)	GlaxoSmithKline Research Triangle Park, NC	asthma	Phase III www.gsk.com
ifetroban (thromboxane A2 receptor antagonist)	Cumberland Pharmaceuticals Nashville, TN	aspirin-induced asthma	Phase II www.cumberlandpharma.com
MEDI3506 (IL-33 inhibitor)	AstraZeneca Wilmington, DE	asthma	Phase II www.astrazeneca.com
MGR001 (fluticasone propionate/salmeterol xinafoate)	Viatis Canonsburg, PA	asthma	Phase III completed www.viatis.com
PT027 (budesonide/salbutamol)	AstraZeneca Wilmington, DE	asthma	Phase III www.astrazeneca.com
RG6173 (anti-tryptase)	Roche/Genentech South San Francisco, CA	asthma	Phase II www.roche.com
SelK2 (PSGL-1 inhibitor)	Tetherex Pharmaceuticals Oklahoma City, OK	asthma	Phase II www.therex.com
STMC-103H (live biotherapeutic product)	Siolta Therapeutics San Carlos, CA	allergic asthma	Phase I www.sioltatherapeutics.com

Asthma
Product Name

Sponsor

Indication

Development Status

TD-8236 (inhaled pan-JAK inhibitor)	Theravance Biopharma South San Francisco, CA	mild asthma	Phase II www.theravance.com
		moderate to severe asthma	Phase I www.theravance.com
TEV-48574	Teva Branded Pharmaceutical Products Parsippany, NJ	asthma	Phase II www.tevausea.com
TEV-53275	Teva Branded Pharmaceutical Products Parsippany, NJ	asthma	Phase II www.tevausea.com
tezepelumab (TSLP inhibitor)	Amgen Thousand Oaks, CA AstraZeneca Wilmington, DE	severe uncontrolled asthma (Breakthrough Therapy)	Phase III www.amgen.com www.astrazeneca.com

Cancer
Product Name

Sponsor

Indication

Development Status

AAA602 (177-Lu-PSMA-R2) (radioligand therapy target PSMA)	Novartis East Hanover, NJ	metastatic castration-resistant prostate cancer (mCRPC)	Phase I www.novartis.com
AAA617 (177-Lu-PSMA-617) (targeted radioligand therapy)	Novartis East Hanover, NJ	mCRPC, metastatic hormone-sensitive prostate cancer (mHSPC)	Phase III www.novartis.com
800TCR (HERV-E targeting TCR therapy)	T-Cure BioScience Sherman Oaks, CA	clear cell kidney cancer	Phase I www.t-cure.com

Cancer Product Name	Sponsor	Indication	Development Status
AB-16B5 (clusterin inhibitor)	Alethia Biotherapeutics Montreal, Canada	non-small cell lung cancer (NSCLC) (combination therapy)	Phase II www.alethisbio.com
AB680 (5-nucleotidase inhibitor)	Arcus Biosciences Hayward, CA	mCRPC	Phase I/II www.arcusbio.com
ABBV-011 (antibody-drug conjugate)	AbbVie North Chicago, IL	small cell lung cancer (SCLC)	Phase I www.abbvie.com
ABBV-184 (surviving TCR/CD3 T cell engager)	AbbVie North Chicago, IL	NSCLC	Phase I www.abbvie.com
ABBV-647/PF-06647020 (PTK7 antibody drug conjugate)	AbbVie North Chicago, IL Pfizer New York, NY	NSCLC	Phase I www.abbvie.com
ABBV-CX-2029 (CD71 probody drug conjugate)	AbbVie North Chicago, IL CytomX Therapeutics South San Francisco, CA	NSCLC	Phase II www.abbvie.com www.cytomx.com
abexinostat (HDAC inhibitor)	Xynomic Pharmaceuticals Dover, DE	kidney cancer	Phase III www.xynomicpharma.com
abivertinib (tyrosine kinase inhibitor)	Sorrento Therapeutics San Diego, CA	NSCLC	Phase III www.sorrentotherapeutics.com

Cancer Product Name	Sponsor	Indication	Development Status
adagloxad simolenin (cancer immunotherapy)	OBI Pharma San Diego, CA	triple negative breast cancer (TNBC)	Phase III www.obipharma.com
Ad-p53 DCV (dendritic cell vaccine)	MultiVir Houston, TX	SCLC (combination therapy)	Phase II www.multivir.com
adagrasib (MRTX849) (KRAS G12C Inhibitor)	Mirati Therapeutics San Diego, CA	2L NSCLC	Phase III www.mirati.com
		1L NSCLC (STK11 co-mutation), 2L~ NSCLC, NSCLC (combination therapy)	Phase II www.mirati.com
ADP-A2AFP (autologous genetically-modified T-cell therapy)	Adaptimmune Philadelphia, PA	liver cancer	Phase I www.adaptimmune.com
ADP-A2M4CD8 (autologous genetically-modified cell therapy)	Adaptimmune Philadelphia, PA	MAGE-A4+ gastric cancer	Phase I www.adaptimmune.com
ADPT01 (LAG3 inhibitor, PD-1 inhibitor)	Novartis East Hanover, NJ	TNBC (immunotherapy combinations)	Phase I www.novartis.com
ADXS-503 (live attenuated Listeria monocytogenes (Lm)-based immunotherapy)	Advaxis Princeton, NJ	NSCLC	Phase I/II www.advaxis.com

Cancer Product Name	Sponsor	Indication	Development Status
ADXS-PSA (live attenuated Listeria monocytogenes (Lm)-based immunotherapy)	Advaxis Princeton, NJ	prostate cancer	Phase I/II www.advaxis.com
AE37 (li-Key immunotherapeutic vaccine)	NuGenerex Immuno-Oncology Miramar, FL	breast cancer, prostate cancer	Phase II www.nugenerexio.com
AK104 (PD-1/CTLA-4 bispecific antibody) ORPHAN DRUG	Akeso Biopharma Fremont, CA	cervical cancer (Fast Track)	Phase II www.asesobio.com
AL101 (gamma secretase inhibitor)	Ayala Pharmaceuticals Wilmington, DE	breast cancer	Phase II www.ayalapharma.com
AL3818 (PTK inhibitor)	Advenchen Laboratories Moorpark, CA	cervical cancer	Phase II/III www.advenchen.com
Alecensa® alectinib	Roche/Genentech South San Francisco, CA	ALK+ NSCLC (adjuvant)	Phase III www.roche.com
ALLO-316 (CAR-T cell therapy)	Allogene South San Francisco, CA	kidney cancer	Phase I www.allogene.com
almonertinib (HS-10296) (EGFR inhibitor)	EQRx Cambridge, MA Hansoh Pharmaceuticals Jiangsu, China	NSCLC	Phase I www.eqr.com

Cancer Product Name	Sponsor	Indication	Development Status
Alunbrig® brigatinib	Takeda Deerfield, IL	2L ALK+ NSCLC (compared to alectinib)	Phase III www.takeda.com
amcenestrant (SAR439859) (SERD)	Sanofi Bridgewater, NJ	1L metastatic breast cancer	Phase III www.sanofi.com
		2L/3L metastatic breast cancer, early breast cancer	Phase II www.sanofi.com
AMG 119 (CAR-T cell therapy)	Amgen Thousand Oaks, CA	SCLC	Phase I www.amgen.com
AMG 160 (acapatamab) (PSMAxCD3 bispecific T cell engager)	Amgen Thousand Oaks, CA	NSCLC, prostate cancer	Phase I www.amgen.com
AMG 199 (MUC17xCD3 bispecific T cell engager)	Amgen Thousand Oaks, CA	gastric/gastroesophageal junction cancer	Phase I www.amgen.com
AMG 404 (anti-PD-1 mAb)	Amgen Thousand Oaks, CA	mCRPC	Phase I www.amgen.com
AMG 509 (bivalent T cell engager)	Amgen Thousand Oaks, CA	prostate cancer	Phase I www.amgen.com
AMG 757 (tarlatamab) (DLL3xCD3 bispecific T cell engager)	Amgen Thousand Oaks, CA	prostate cancer, SCLC	Phase I www.amgen.com

Cancer Product Name	Sponsor	Indication	Development Status
AMG 910 (CLDNxCD3 bispecific T cell engager)	Amgen Thousand Oaks, CA	gastric/gastroesophageal junction cancer	Phase I www.amgen.com
Ampligen® rintatolimod	AIM ImmunoTech Ocala, FL	early-stage prostate cancer, TNBC	Phase II www.aimimmuno.com
		early-stage TNBC	Phase I www.aimimmuno.com
Anktiva™ inbakicept (N-803)	ImmunityBio Culver City, CA	1L NSCLC (monotherapy and combination therapy)	Phase III www.immunitybio.com
		2L+ NSCLC (+PD-L1 haNK), 3L+ TNBC (PD-L1 haNK)	Phase II www.immunitybio.com
		3L+ TNBC (+aldox and PD-L1haNK)	Phase I www.immunitybio.com
APG-1252 (Bcl-2/NclxL inhibitor) ORPHAN DRUG	Ascentage Pharma Rockville, MD	SCLC	Phase I/II www.ascentagepharma.com
APX005M (IgG1 CD40 agonistic antibody) ORPHAN DRUG	Apexigen San Carlos, CA	gastroesophageal junction cancer	Phase II www.apexigen.com
		NSCLC (+nivolumab)	Phase I/II completed www.apexigen.com

Cancer Product Name	Sponsor	Indication	Development Status
ARO-HIF2 (siRNA therapeutic)	Arrowhead Pharmaceuticals Pasadena, CA	kidney cancer	Phase I www.arrowheadpharma.com
ARV-110 (androgen receptor degradation enhancer)	Arvinas New Haven, CT	mCRPC (Fast Track)	Phase II www.arvinas.com
ARV-471 (estrogen receptor degrader)	Arvinas New Haven, CT	ER+ HER2- breast cancer	Phase II www.arvinas.com
ARX788 (anti-HER2 antibody-drug conjugate) ORPHAN DRUG	Ambrx La Jolla, CA	metastatic breast cancer	Phase II www.ambrx.com
		gastric cancer	Phase I www.ambrx.com
ATA2271 (mesothelin CAR-T cell therapy)	Bayer Pharmaceutical Whippany, NJ	mesothelioma	Phase I www.pharma.bayer.com
AVB-500 (GAS6-AXL pathway inhibitor)	Aravive Houston, TX	clear cell kidney cancer	Phase I www.aravive.com
axalimogene filolisbac (cancer vaccine) ORPHAN DRUG	Advaxis Monmouth Junction, NJ	cervical cancer (Fast Track)	Phase III www.advaxis.com
AZD2811 (aurora kinase B inhibitor)	AstraZeneca Wilmington, DE	extensive-stage SCLC (+durvalumab)	Phase II www.astrazeneca.com

Cancer Product Name	Sponsor	Indication	Development Status
BA3011 (CAB-AXL-ADC)	BioAlta San Diego, CA	AXL-expressing NSCLC	Phase II www.bioalta.com
BA3021 (CAB-ROR2-ADC)	BioAlta San Diego, CA	ROR2-expressing NSCLC	Phase I/II www.bioalta.com
balixafortide (POL6326) (CXCR4 inhibitor)	Polyphor Allschwil, Switzerland	breast cancer (Fast Track)	Phase III www.polyphor.com
balstilimab (anti-PD-1 antibody)	Agenus Lexington, MA	cervical cancer (Fast Track)	application submitted www.agenusbio.com
		cervical cancer (+zalifrelimab) (Fast Track)	Phase II www.agenusbio.com
BAT1706 (bevacizumab biosimilar)	Bio-Thera Solutions Guangzhou, China	cervical cancer, NSCLC, kidney cancer	application submitted www.bio-thera.com
Bavencio [®] avelumab	EMD Serono Rockland, MA Pfizer New York, NY	1L NSCLC	Phase III www.emdserono.com www.pfizer.com
bavituximab (phosphatidylserine inhibitor)	OncXerna Therapeutics Waltham, MA	gastric cancer	Phase II www.oncxerna.com
BAY2315497 (PSMA-TTC) (PSMA-targeted thorium conjugate)	Bayer Pharmaceuticals Whippany, NJ	prostate cancer	Phase I www.pharma.bayer.com

Cancer Product Name	Sponsor	Indication	Development Status
bemarituzumab (FPA-144) (anti-FGFR2B antibody) ORPHAN DRUG	Amgen Thousand Oaks, CA	1L gastric/gastroesophageal junction cancer (Breakthrough Therapy)	Phase II www.amgen.com
bemcentinib (RTK inhibitor)	BerGenBio Bergen, Norway	NSCLC (+pembrolizumab)	Phase II www.bergenbio.com
bempegaldesleukin (natural killer cell stimulant)	Nektar Therapeutics San Francisco, CA	NSCLC (+pembrolizumab)	Phase I/II www.nektar.com
berzosertib (M6620) (ATR inhibitor)	EMD Serono Rockland, MA	SCLC (+topotecan)	Phase II www.emdserono.com
BI 764532 (DLL3/CD3 bispecific antibody)	Boehringer Ingelheim Ridgefield, CT	SCLC	Phase I www.boehringer-ingelheim.com
BI 836880 + BI 754091 (VEGF/Ang-2 antibody / PD-1 antibody)	Boehringer Ingelheim Ridgefield, CT	NSCLC	Phase I www.boehringer-ingelheim.com
BI 905711 (TRAIL2/CDH217 antibody)	Boehringer Ingelheim Ridgefield, CT	gastric cancer	Phase I www.boehringer-ingelheim.com
bicalutamide implant (androgen receptor antagonist)	Alessa Therapeutics San Carlos, CA	prostate cancer	Phase I www.alessatherapeutics.com

Cancer Product Name	Sponsor	Indication	Development Status
bintrafusp alfa (TGFB trap/anti-PD-L1)	EMD Serono Rockland, MA GlaxoSmithKline Research Triangle Park, NC	1L biliary cancer	Phase II/III www.emdserono.com
		1L/2L NSCLC, 2L cervical cancer, locally advanced NSCLC, TNBC	Phase II www.emdserono.com
		1L cervical cancer	Phase I www.emdserono.com
BIO-11006 (myristoylated alanine rich C kinase substrate inhibitor)	BioMarck Pharmaceuticals Durham, NC	NSCLC	Phase II www.biomarck.com
BLU-945 (EGFR antagonist)	Blueprint Medicines Cambridge, MA	EGFR+ NSCLC	Phase I www.blueprintmedicines.com
Braftovi® + Mektovi encorafenib + binimetinib	Pfizer New York, NY	1L/2L BRAF-mutant NSCLC	Phase II www.pfizer.com
BMS-986012 (anti-fucosyl GM1 inhibitor)	Bristol-Myers Squibb Princeton, NJ	extensive-stage SCLC (combination therapy)	Phase II www.bms.com
BNT112 (mRNA immunotherapy)	BioNTech Mainz, Germany	prostate cancer	Phase I/II www.biontech.de
BPX-601 (CAR T-cell therapy)	Bellicum Pharmaceuticals Houston, TX	metastatic prostate cancer	Phase I/II www.bellicum.com

Cancer Product Name	Sponsor	Indication	Development Status
BXCL701 (innate immunity activator)	BioXcel Therapeutics New Haven, CT	mCRPC (combination therapy)	Phase II www.bioxceltherapeutics.com
Cabometyx® cabozantinib ORPHAN DRUG	Exelixis Alameda, CA	mCRPC (combination therapy), 1L kidney cancer (combination therapy), liver cancer (combination therapy)	Phase III www.exelixis.com
		breast cancer, CRPC, kidney cancer, liver cancer, NSCLC, gastric/ gastroesophageal junction cancer	Phase I www.exelixis.com
camizestrant (AZD9833) (SERD)	AstraZeneca Wilmington, DE	1L HR+ HER2- breast cancer	Phase III www.astrazeneca.com
		ER+ breast cancer	Phase II www.astrazeneca.com
camrelizumab (PD-1 inhibitor)	Hengrui USA Princeton, NJ	1L liver cancer (+apatinib)	Phase III www.hengruiusa.com
CAN-2409 aglatimagene besadenovec (cancer suicide gene therapy) ORPHAN DRUG	Candel Therapeutics Needham, MA	localized, intermediate/high risk prostate cancer (Fast Track)	Phase III www.candeltx.com
		NSCLC (+PD-1/PD-L1), prostate cancer (active surveillance)	Phase II www.candeltx.com
		resectable NSCLC	Phase I www.candeltx.com

Cancer Product Name	Sponsor	Indication	Development Status
capivasertib (AZD5363) (Akt inhibitor)	AstraZeneca Wilmington, DE	1L metastatic TNBC, inoperable or metastatic breast cancer, PTEN-deficient hormone sensitive prostate cancer	Phase III www.astrazeneca.com
		prostate cancer	Phase II www.astrazeneca.com
CC-90011 (LSD1 inhibitor)	Bristol-Myers Squibb Princeton, NJ	1L extensive-stage SCLC	Phase II www.bms.com
CC-94676 (androgen receptor ligand directed degrader-AR-LDD)	Bristol-Myers Squibb Princeton, NJ	prostate cancer	Phase I www.bms.com
CCW702 (cancer immunotherapy)	AbbVie North Chicago, IL Calibr La Jolla, CA	CRPC	Phase I www.abbvie.com
cetrelimab (JNJ-63723283) (PD-1 Inhibitor)	Janssen Research & Development Raritan, NJ	CRPC (+apalutamide)	Phase I www.janssen.com
checkpoint cell therapy (CISH inactivated tumor infiltrating lymphocyte cell therapy)	Intima Bioscience New York, NY	gastrointestinal cancer	Phase I/II www.intimabioscience.com
ciforadenant (A2AR inhibitor)	Corvus Pharmaceuticals Burlingame, CA	kidney cancer	Phase I/II www.corvuspharma.com

Cancer Product Name	Sponsor	Indication	Development Status
cirmtuzumab (ROR1 antagonist)	Oncternal Therapeutics San Diego, CA	breast cancer	Phase I www.oncternal.com
CK-101 (EGFR inhibitor) ORPHAN DRUG	Checkpoint Therapeutics New York, NY	NSCLC	Phase I/II www.checkpointtx.com
CLN-081 (EGFR Exon 20 mutation inhibitor)	Cullinan Oncology Cambridge, MA	NSCLC	Phase I/II www.cullinanoncology.com
CMN-001 (dendritic cell-based immunotherapy)	ColImmune Durham, NC	kidney cancer	Phase II www.coimmune.com
cobolimab (anti-TIM3 antibody)	AnaptysBio San Diego, CA GlaxoSmithKline Research Triangle Park, NC	NSCLC	Phase II www.anaptysbio.com www.gsk.com
CONV 01-alpha (peptide receptor radionuclide therapy)	Convergent Therapeutics Chappaqua, NY	prostate cancer	Phase I/II
Cosela® trilaciclib	G1 Therapeutics Research Triangle Park, NC	1LTNBC, 2L TNBC (post-checkpoint treatment)	Phase III www.g1therapeutics.com
		2L/3L NSCLC (post-checkpoint treatment), neoadjuvant breast cancer	Phase II www.g1therapeutics.com

Cancer Product Name	Sponsor	Indication	Development Status
CPP-1X (ornithine decarboxylase inhibitor) ORPHAN DRUG	Cancer Prevention Pharmaceuticals Tucson, AZ	gastric cancer	Phase II www.canprevent.com
crenolanib (FLT3/PDGFR α / β inhibitor)	AROG Pharmaceuticals Plano, TX	gastrointestinal stromal tumor (Fast Track)	Phase III www.arogpharma.com
		gastric cancer	Phase I www.arogpharma.com
CT041 (claudin18.2 CAR T-cell therapy) ORPHAN DRUG	CARsgen Therapeutics Shanghai, China	gastric cancer	Phase I
CTT1403 (PSMA-targeted radiopharmaceutical)	Cancer Targeted Technology Woodinville, WA	mCRPC	Phase I www.cancertargetedtechnology.com
CVM-1118 (angiogenesis inhibitor)	TaiRx Taipei, Taiwan	liver cancer	Phase II www.trx.com.tw
CX072+CX2009 (PD-L1 probody immunotherapy + CD166 probody drug conjugate)	CytomX Therapeutics South San Francisco, CA	TNBC	Phase II www.cytomx.com
CX2009 (praluzatamab ravtansine) (CD166 probody drug conjugate)	CytomX Therapeutics South San Francisco, CA	ER+/PR+ HER2- breast cancer	Phase II www.cytomx.com
CYTO-402 (proenkephalin analog)	Cytocom Fort Collins, CO	liver cancer	Phase I www.cytocom.com

Cancer Product Name	Sponsor	Indication	Development Status
D-0502 (SERD)	InventisBio Florham Park, NJ	ER+ HER2- breast cancer	Phase I www.inventisbio.com
D-1553 (KRAS inhibitor)	InventisBio Florham Park, NJ	NSCLC	Phase I www.inventisbio.com
datopotamab deruxtecan (DS-1062) (anti-TROP2-ADC)	Daiichi Sankyo Basking Ridge, NJ	NSCLC (without actionable mutation)	Phase III www.dsi.com
		actionable mutated NSCLC	Phase II www.dsi.com
		HR+ breast cancer, NSCLC, TNBC (monotherapy and combination therapy)	Phase I www.dsi.com
DCVAC/Pca (stapuldencel-T) (active cellular immunotherapy)	SOTIO Boston, MA	CRPC	Phase III www.sotio.com
derazantinib (FGFR kinase inhibitor) ORPHAN DRUG	Basilea Pharmaceutica Basel, Switzerland	cholangiocarcinoma	Phase II www.basilea.com
		gastric cancer (combination therapy)	Phase I/II www.basilea.com
DHP107 (oral paclitaxel)	Daehwa Pharmaceutical Seoul, South Korea	recurrent breast cancer	Phase II www.dhpharm.co.kr

Cancer Product Name	Sponsor	Indication	Development Status
DKN-01 (DKK1 protein inhibitor) ORPHAN DRUG	Leap Therapeutics Cambridge, MA	hepatobiliary cancer (+nivolumab)	Phase II www.leaptx.com
		prostate cancer (monotherapy and combination therapy), hepatobiliary cancer (+sorfenib), gastroesophageal cancer (combination therapy)	Phase I/II www.leaptx.com
DocePLUS™ albumin-stabilized PEGylated liposomal docetaxel ORPHAN DRUG	Plus Therapeutics Austin, TX	SCLC	Phase I www.plustherapeutics.com
domvanalimab (AB154) (TIGIT inhibitor)	Arcus Biosciences Hayward, CA	1L PD-L1+ NSCLC (combination therapy)	Phase III www.arcusbio.com
		1L NSCLC (combination therapy)	<u>Phase II</u> www.arcusbio.com
dovitinib (pan-tyrosine kinase inhibitor)	Allarity Therapeutics Cambridge, MA	kidney cancer	Phase III www.allarity.com
DPV-001 (cancer vaccine)	UbiVac Portland, OR	adjuvant NSCLC	Phase II www.ubivac.com
		TNBC, prostate cancer	Phase I www.ubivac.com

Cancer Product Name	Sponsor	Indication	Development Status
DS-6000 (CDH6-directed ADC)	Daiichi Sankyo Basking Ridge, NJ	kidney cancer	Phase I www.dsi.com
DS-6157 (anti-GPR20-ADC)	Daiichi Sankyo Basking Ridge, NJ	gastrointestinal stromal tumors	Phase I www.dsi.com
DZD1516 (HER2 tyrosine kinase inhibitor)	Dizal Pharmaceuticals Shanghai, China	HER2+ breast cancer	Phase I www.dizalpharma.com
DZD9008 (EGFR inhibitor)	Dizal Pharmaceuticals Shanghai, China	NSCLC	Phase I www.dizalpharma.com
eftilagimod alpha (IMP321) (LAG3 fusion protein)	Immutep Sydney, Australia	NSCLC (+pembrolizumab)	Phase II www.immutep.com
EG12014 (trastuzumab biosimilar)	EirGenix New Taipei City, Taiwan	HER2+ early breast cancer	Phase III www.eirgenix.com
EGF816 (nazartinib) (EGFR inhibitor)	Novartis East Hanover, NJ	NSCLC (combination therapy)	Phase I www.novartis.com
elacestrant (RAD1901) (SERD)	Radius Health Waltham, MA	ER+ breast cancer (Fast Track)	Phase III www.radiuspharm.com
ELI-002 (amphiphile cancer vaccine)	Elicio Therapeutics Cambridge, MA	NSCLC	Phase I/II www.elicio.com

Cancer Product Name	Sponsor	Indication	Development Status
eltanexor (KPT-8602) (SINE inhibitor)	Karyopharm Therapeutics Newton, MA	prostate cancer	Phase I www.karyopharm.com
encequidar + oral paclitaxel (P-gp inhibitor)	Athenex Oncology Buffalo, NY	metastatic breast cancer	application submitted www.athenexoncology.com
		neoadjuvant breast cancer (combination therapy)	Phase II www.athenexoncology.com
		gastric cancer (combination therapy)	Phase I www.athenexoncology.com
endoxifen (tamoxifen metabolite)	Atossa Therapeutics Seattle, WA	breast cancer	Phase II www.atossatherapeutics.com
Enhertu® fam-trastuzumab deruxtecan-nxki ORPHAN DRUG	AstraZeneca Wilmington, DE Daiichi Sankyo Basking Ridge, NJ	1L HER2+ breast cancer, 2L/3L HER2+ breast cancer, HER2-low breast cancer, HER2+ breast cancer (neoadjuvant), previously-treated HER2+ breast cancer, 2L HER2+ gastric cancer	Phase III www.dsi.com www.astrazeneca.com
		2L HER2+ mutated NSCLC (Breakthrough Therapy), 2L HER2-mutated NSCLC, 2L NSCLC (+durvalumab), TNBC	Phase II www.dsi.com www.astrazeneca.com
		HER2-low breast cancer, 1L/2L~HER2+ breast cancer, 1L/2L~HER2+ gastric cancer, breast cancer (combination therapy), NSCLC (combination therapy)	Phase I www.dsi.com www.astrazeneca.com

Cancer Product Name	Sponsor	Indication	Development Status
ensartinib (ALK inhibitor)	Xcovery Palm Beach Gardens, FL	1L NSCLC	Phase III www.xcovery.com
		2L NSCLC	Phase II www.xcovery.com
entinostat (HDAC inhibitor)	Syndax Pharmaceuticals Waltham, MA	HR+ HER2- breast cancer (combination therapy) (Breakthrough Therapy), NSCLC	Phase III www.syndax.com
epacadostat (IDO1 inhibitor)	Incyte Wilmington, DE	metastatic kidney cancer	Phase III www.incyte.com
EPI-7386 (androgen receptor antagonist)	ESSA Pharma Houston, TX	mCRPC (Fast Track)	Phase I www.essapharma.com
eprenetapopt (APR-246) (p53 stimulant)	Aprea Boston, MA	gastric cancer, NSCLC	Phase I www.aprea.com
eRapa™ rapamycin micro-encapsulated	Emtora Biosciences San Antonio, TX	low-grade prostate cancer	Phase I completed www.emtorabio.com
Erleada® apalutamide	Janssen Research & Development Raritan, NJ	high-risk prostate cancer, localized prostate cancer	Phase III www.janssen.com
ET140203 (CAR-T cell therapy)	Eureka Therapeutics Emeryville, CA	liver cancer	Phase I/II www.eurekatherapeutics.com

Cancer Product Name	Sponsor	Indication	Development Status
etrumadenant (A2A/A2B receptor antagonist)	Arcus Biosciences Hayward, CA	NSCLC (combination therapy), CRPC (combination therapy)	Phase II www.arcusbio.com
exicorilant (GR II antagonist)	Corcept Therapeutics Menlo Park, CA	CRPC (+enzalutamide)	Phase II www.corcept.com
fexapotide (NX-1207) (apoptosis stimulant)	Nymox Pharmaceutical Hasbrouck Heights, NJ	early-stage prostate cancer	Phase II www.nymox.com
fimaporfin delivered gemcitabine ORPHAN DRUG	PCI Biotech Oslo, Norway	cholangiocarcinoma	Phase II www.pcibiotech.no
fisogatinib (FGFR4 inhibitor) ORPHAN DRUG	Blueprint Medicines Cambridge, MA	liver cancer	Phase I www.blueprintmedicines.com
FKB238 (bevacizumab biosimilar)	Centus Biotherapeutics Cambridge, United Kingdom	NSCLC	Phase III www.centusbiotherapeutics.com
FOR46-001 (anti-CD46 antibody-drug conjugate)	Fortis Therapeutics San Diego, CA	mCRPC	Phase I www.fortistx.com
Fotivda [®] tivozanib	AVEO Oncology Boston, MA	kidney cancer (combination therapy)	Phase II www.aveooncology.com
FT-7051 (IDH1m inhibitor)	FORMA Therapeutics Watertown, MA	mCRPC	Phase I www.formatherapeutics.com

Cancer Product Name	Sponsor	Indication	Development Status
fulvestrant (injectable formulation)	Eagle Pharmaceuticals Woodcliff Lake, NJ	breast cancer	Phase I www.eagleus.com
galinpepimut-S (WT1 cancer vaccine)	Sellas Life Sciences New York, NY	malignant pleural mesothelioma (combination therapy)	Phase I www.sellaslifesciences.com
GC4711 (superoxide dismutase modulator)	Galera Therapeutics Malvern, PA	NSCLC (+stereotactic body radiation therapy)	Phase II www.galeratx.com
gedatolisib (mTOR/PI3K inhibitor)	Celcuity Therapeutics New York, NY	metastatic breast cancer (combination therapy)	Phase I www.celcuity.com
GEN2 (cancer immunotherapeutic)	GenVivo San Marino, CA	liver cancer	Phase I www.genvivoinc.com
gevokizumab (VPM087) (IL1B antagonist)	Novartis East Hanover, NJ	kidney cancer (combination therapy)	Phase I www.novartis.com
GLR2007 (CDK4/6 inhibitor)	Gan & Lee Pharmaceuticals Bridgewater, NJ	NSCLC	Phase I/II www.ganlee.us
GMI-1359 (E-selectin/CXCR4 antagonist)	GlycoMimetics Rockville, MD	HR+ metastatic breast cancer	Phase I www.glycomimetics.com
GNOS-PV02 (personalized neoantigen-targeted immunotherapy)	Geneos Therapeutics Plymouth Meeting, PA	liver cancer (combination therapy)	Phase I/II www.gneostx.com

Cancer Product Name	Sponsor	Indication	Development Status
GP2 (HER2/Neu GP2 immunotherapy)	Greenwich Life Sciences Stafford, TX	prevent breast cancer recurrences following surgery	Phase II www.greenwichlifesciences.com
Graspa [®] eryaspase (asparaginase encapsulated)	Erytech Pharma Cambridge, MA	TNBC	Phase II www.erytech.com
GRN-1201 (peptide vaccine)	BrightPath Biotherapeutics Tokyo, Japan	NSCLC (+pembrolizumab)	Phase II www.brightpathbio.com
GS-4224 (oral PD-L1 inhibitor)	Gilead Sciences Foster City, CA	NSCLC	Phase I www.gilead.com
GSK3377794 (letetresgene autoleucel)	GlaxoSmithKline Research Triangle Park, NC	NY-ESO-1/LAGE-1a-positive advanced NSCLC	Phase I/II www.gsk.com
GT103 (complement factor H inhibitor)	Grid Therapeutics Durham, NC	NSCLC	Phase I/II www.gridtherapeutics.com
H3B-6527 (FGFR4 inhibitor) ORPHAN DRUG	H3 Biomedicine (Eisai) Cambridge, MA	liver cancer	Phase I www.h3biomedicine.com
H3B-6545 (estrogen receptor-alpha inhibitor)	H3 Biomedicine (Eisai) Cambridge, MA	breast cancer	Phase I/II www.h3biomedicine.com
		breast cancer (combination therapy)	Phase I www.h3biomedicine.com

Cancer Product Name	Sponsor	Indication	Development Status
HC-1119 (androgen receptor antagonist)	Hinova Pharmaceuticals USA San Diego, CA	mCRPC	Phase III www.hinovapharma.com
HC-5404-FU (PERK inhibitor)	HiberCell New York, NY	HER2+ breast cancer, gastric cancer, kidney cancer, SCLC	Phase I www.hibercell.com
Hepzato™ Kit melphalan hepatic delivery system ORPHAN DRUG	Delcath Systems New York, NY	liver metastases from ocular melanoma (Fast Track)	Phase III www.delcath.com
		intrahepatic cholangiocarcinoma	Phase II/III www.delcath.com
HPN328 (DLL2 T cell engager)	Harpoon Therapeutics South San Francisco, CA	SCLC	Phase I/II www.harpoontx.com
HPN424 (PSMA targeting T-cell engager)	Harpoon Therapeutics South San Francisco, CA	prostate cancer	Phase I www.harpoontx.com
huMNC2-CAR44 T cells (anti-MUC1 CAR-T cell therapy)	Minerva Biotechnologies Waltham , MA	breast cancer	Phase I www.minervabio.com
I-131-1095 (PSMA-targeted radiotherapy)	Progenics Pharmaceuticals New York, NY	mCRPC	Phase II www.progenics.com
Ibrance® palbociclib	Pfizer New York, NY	ER+ HER2+ metastatic breast cancer	Phase III www.pfizer.com

Cancer Product Name	Sponsor	Indication	Development Status
Ilaris® canakinumab	Novartis East Hanover, NJ	1L NSCLC, adjuvant NSCLC	Phase III www.novartis.com
Imfinzi® durvalumab ORPHAN DRUG	AstraZeneca Wilmington, DE	locally-advanced cervical cancer, 1L biliary tract cancer, liver cancer, 1L liver cancer (combination therapy), 1L limited-stage SCLC, 1L NSCLC, locally-advanced NSCLC, gastric cancer (neoadjuvant/adjuvant)	Phase III www.astrazeneca.com
		1L TNBC, biliary cancer, gastric cancer, prostate cancer (+AZD4635), NSCLC, extensive-stage SCLC	Phase II www.astrazeneca.com
		NSCLC (combination therapy), SCLC (combination therapy)	Phase I www.astrazeneca.com
Imprime PGG cancer immunotherapy	HiberCell New York, NY	metastatic breast cancer (+immune checkpoint inhibitor)	Phase II www.hibercell.com
IMU-201 (PD1-Vaxx) (PD-L1 immunotherapy)	Imugene Sydney, Australia	NSCLC	Phase I www.imugene.com
INO-5151 (DNA vaccine)	Inovio Pharmaceuticals Plymouth Meeting, PA	prostate cancer	Phase II www.inovio.com
IONIS-AR-2.5-RX (androgen receptor antagonist)	Ionis Pharmaceuticals Carlsbad, CA	prostate cancer	Phase II www.ionispharma.com

Cancer Product Name	Sponsor	Indication	Development Status
IPI-549 (eganelisib) (PIK3y inhibitor)	Infinity Pharmaceuticals Cambridge, MA	1L TNBC, breast cancer (combination therapy) (Fast Track) 1L kidney cancer (combination therapy)	Phase II www.infi.com
		TNBC (combination therapy)	Phase I www.infi.com
irofulven (LP-100)	Allarity Therapeutics Cambridge, MA Lantern Pharma Dallas, TX	mCRPC	Phase II www.allarity.com www.lanternpharma.com
IRX4204 (RXR agonist)	Io Therapeutics Santa Ana, CA	HER2+ breast cancer, NSCLC, prostate cancer	Phase II www.io-therapeutics.com
JNJ-69086420 (actinium-225-labeled antibody)	Janssen Research & Development Raritan, NJ	prostate cancer	Phase I www.janssen.com
JNJ-73841937 (lazertinib) (EGFR antagonist)	Janssen Research & Development Raritan, NJ	NSCLC	Phase III www.janssen.com
JTX-2011 (vopratelimab) (ICOS stimulator)	Jounce Therapeutics Cambridge, MA	NSCLC (combination therapy)	Phase II www.jouncetx.com
JTX-4014 (pimivalimab) (PD-1 antibody)	Jounce Therapeutics Cambridge, MA	NSCLC (combination therapy and monotherapy)	Phase II www.jouncetx.com
KABE (abiraterone)	Austhera Biosciences Georgetown, TX	prostate cancer	Phase I www.austherabio.com

Cancer Product Name	Sponsor	Indication	Development Status
Kadcyla® ado-trastuzumab emtansine	Genentech/Roche South San Francisco, CA	2L~ HER2+ PD-L1+ metastatic breast cancer	Phase III www.roche.com
Keytruda® pembrolizumab	Merck Kenilworth, NJ	high-risk early stage TNBC (Breakthrough Therapy)	application submitted www.merck.com
		biliary tract cancer, prostate cancer, mesothelioma	Phase III www.merck.com
Kisqali® ribociclib	Novartis East Hanover, NJ	HR+ HER2- early breast cancer (adjuvant)	Phase III www.novartis.com
KN026 (anti-HER2 antibody)	Jiangsu Alphamab Biopharmaceuticals Suzhou, China	breast cancer, gastric/ gastroesophageal junction cancer	Phase I www.alphamabonc.com
KPG-121 (angiogenesis inhibitor)	Kangpu Biopharmaceuticals Shanghai, China	CRPC	Phase I www.kangpugroup.com
ladiratumumab vedotin (antibody-drug conjugate)	Merck Kenilworth, NJ Seagen Bothell, WA	TNBC (monotherapy and +pembrolizumab)	Phase II www.merck.com www.seagen.com
		metastatic breast cancer	Phase I www.merck.com www.seagen.com
LAE001 (androgen synthesis enzyme inhibitor)	Laekna Therapeutics Shanghai, China	mCRPC	Phase I/II www.laeknatp.com

Cancer Product Name	Sponsor	Indication	Development Status
lasofoxifene (SERM)	Sermonix Pharmaceuticals Columbus, OH	ER+ HER2- breast cancer with ESR1 mutations (Fast Track)	Phase II www.sermonixpharma.com
LB 100 (PP2A inhibitor)	Lixte Biotechnology East Setauket, NY	SCLC	Phase II www.liخته.com
Lenvima® + Keytruda® lenvatinib + pembrolizumab	Eisai Woodcliff Lake, NJ Merck Kenilworth, NJ	1L metastatic liver cancer, advanced unresectable kidney cancer	application submitted www.eisai.com www.merck.com
		gastric cancer, NSCLC	Phase III www.eisai.com www.merck.com
		biliary tract cancer (Breakthrough Therapy)	Phase II www.eisai.com www.merck.com
lerociclib (CDK4/6 inhibitor)	EQRx Cambridge, MA	breast cancer, NSCLC	Phase I/II www.eqr.com
leronlimab (CCR5 antagonist)	CytoDyn Vancouver, WA	TNBC (Fast Track)	Phase II www.cytodyn.com
Libtayo® cemiplimab-rwlc	Regeneron Pharmaceuticals Tarrytown, NY Sanofi Bridgewater, NJ	1L NSCLC (combination therapy), 2L cervical cancer (Fast Track)	Phase III www.sanofi.com

Cancer Product Name	Sponsor	Indication	Development Status
lifileucel (TIL autologous cell therapy) ORPHAN DRUG	Iovance Biotherapeutics San Carlos, CA	cervical cancer	Phase III www.iovance.com
LN-145 (TIL autologous cell therapy)	Iovance Biotherapeutics San Carlos, CA	NSCLC	Phase II www.iovance.com
LP-300 (glutaredoxin/thioredoxin modulator)	Lantern Pharma Dallas, TX	NSCLC	Phase I www.lanternpharma.com
Lumakras™ sotorasib ORPHAN DRUG	Amgen Thousand Oaks, CA	NSCLC (Breakthrough Therapy)	application submitted www.amgen.com
LXH254 (naporafenib) (Raf kinase inhibitor)	Novartis East Hanover, NJ	NSCLC	Phase I www.novartis.com
LY3295668 (aurora A kinase inhibitor)	Lilly Indianapolis, IN	extensive-stage SCLC	Phase I www.lilly.com
LY3484356 (SERD)	Lilly Indianapolis, IN	metastatic breast cancer	Phase I www.lilly.com
LYC-55716 (RORγ agonist)	Lycera Ann Arbor, MI	NSCLC (combination therapy)	Phase I www.lycera.com

Cancer Product Name	Sponsor	Indication	Development Status
Lynparza® olaparib	AstraZeneca Wilmington, DE Merck Kenilworth, NJ	gBRCA adjuvant breast cancer, gBRCA metastatic breast cancer, prostate cancer (combination therapy) NSCLC (+pembrolizumab), SCLC (+pembrolizumab)	Phase III www.astrazeneca.com www.merck.com
Margenza™ margetuximab ORPHAN DRUG	MacroGenics Rockville, MD	HER2-positive gastric/ gastroesophageal junction cancer	Phase III www.macrogenics.com
mavorixafor (CXCR4 inhibitor)	X4 Pharmaceuticals Cambridge, MA	kidney cancer (+axitinib)	Phase II www.x4pharma.com
MB-105 (PSCA CAR-T cell therapy)	Mustang Bio Worcester, MA City of Hope Medical Center Duarte, CA	mCRPC	Phase I www.mustangbio.com
MBM-02 (tempol) (stable free radical scavenger antioxidant)	Matrix Biomed Irvine, CA	prostate cancer (biochemical recurrence)	Phase II www.matrixbiomed.com
MCLA-128 (zenocutuzumab) (HER2xHER3 bispecific antibody)	Merus Cambridge, MA	metastatic breast cancer	Phase II www.merus.nl
MEDI5752 (PD-1xCTLA-4 bispecific antibody)	AstraZeneca Wilmington, DE	kidney cancer (+axitinib)	Phase I www.astrazeneca.com

Cancer Product Name	Sponsor	Indication	Development Status
MEN1611 (PI3K inhibitor)	Menarini Florence, Italy	metastatic breast cancer (combination therapy)	Phase I www.menarini.com
MGC936 (anti-ADAM9 ADC)	ImmunoGen Waltham, MA	gastric cancer, NSCLC, TNBC	Phase I www.immunogen.com
mifepristone (glucocorticoid/progesterone receptor antagonist)	Corcept Therapeutics Menlo Park, CA	GR+ TNBC (+nab-paclitaxel), HER2- breast cancer (+pembrolizumab), CRPC (+enzalutamide)	Phase II www.corcept.com
MK-1308 (quanvonlimab) (CTLA4 inhibitor)	Merck Kenilworth, NJ	NSCLC (+pembrolizumab), kidney cancer (+pembrolizumab)	Phase II www.merck.com
MK-1308A quavonlimab/pembrolizumab)	Merck Kenilworth, NJ	kidney cancer	Phase III www.merck.com
MK-4280 (CD223 antigen inhibitor)	Merck Kenilworth, NJ	NSCLC (+pembrolizumab)	Phase II www.merck.com
MK-4830 (ILT4/LILRB2 inhibitor)	Merck Whitehouse Station, NJ	NSCLC	Phase II www.merck.com
MK-5890 (anti-CD27 antibody)	Merck Kenilworth, NJ	NSCLC (+pembrolizumab)	Phase II www.merck.com

Cancer Product Name	Sponsor	Indication	Development Status
MK-6482 (belzutifan) (HIF-2 α inhibitor) ORPHAN DRUG	Merck Kenilworth, NJ	VHL-kidney cancer (Breakthrough Therapy)	application submitted www.merck.com
		kidney cancer	Phase III www.merck.com
MK-7684A (vibostolimab/pembrolizumab)	Merck Whitehouse Station, NJ	NSCLC	Phase II www.merck.com
mobocertinib (TAK-788) (ERBB 2 receptor antagonist) ORPHAN DRUG	Takeda Deerfield, IL	2L+ NSCLC with EGFR exon 20 insertion mutation (Breakthrough Therapy)	application submitted www.takeda.com
		1L NSCLC w/EGFR exon 20 insertion mutation	Phase III www.takeda.com
ModraDoc006/r (docetaxel plus ritonavir)	Modra Pharmaceuticals Amsterdam, Netherlands	metastatic prostate cancer	Phase II www.modrapharmaceuticals.com
MRG002 (antibody drug conjugate)	Miracogen Shanghai, China	gastric/gastroesophageal junction cancer	Phase I/II www.miracogen.com.cn
mRNA-5671/V941 (KRAS vaccine)	Moderna Therapeutics Cambridge, MA Merck Kenilworth, NJ	NSCLC (monotherapy and pembrolizumab)	Phase I www.modernatx.com www.merck.com
MSI-1436 (PTP-1B inhibitor)	DepYmed Farmingdale, NY	HER2+ breast cancer	Phase I www.depymedinc.com

<u>Cancer Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
MVI-118 (DNA cancer vaccine)	Madison Vaccines Madison, WI	prostate cancer (+pembrolizumab)	Phase II www.madisonvaccines.com
MVI-816 (DNA plasmid vaccine)	Madison Vaccines Madison, WI	prostate cancer (+pembrolizumab)	Phase II www.madisonvaccines.com
MYL-14020 (bevacizumab biosimilar)	Viatrix Canonsburg, PA	cervical cancer, NSCLC, kidney cancer	application submitted www.viatrix.com
namodenoson (CF102) (A3AR agonist) ORPHAN DRUG	Can-Fite BioPharma Waltham, MA	liver cancer (Fast Track)	Phase II www.canfite.com
NanoPac [®] submicron particle paclitaxel	NanOlogy Fort Worth, TX	lung cancer	Phase II www.nanology.us
NBE-002 (ROR-1 antibody drug conjugate)	NBE-Therapeutics Basel, Switzerland	TNBC	Phase I/II www.nbe-therapeutics.com
NBF-006 (siRNA-based lipid nanoparticle)	Nitto Biopharma San Diego, CA	NSCLC	Phase I www.nittobiopharma.com
nelipepimut-S (E75 cancer vaccine)	Sellas Life Sciences New York, NY	HER2+ breast cancer (combination therapy) (Fast Track)	Phase II completed www.sellaslifesciences.com
Nerlynx [®] neratinib	Puma Biotechnology Los Angeles, CA	HER2-mutant HR+ breast cancer, HER2-mutant cervical cancer, HER2-mutant NSCLC	Phase II www.pumabiotechnology.com

Cancer Product Name	Sponsor	Indication	Development Status
niraparib (PARP inhibitor)	Janssen Research & Development Raritan, NJ	1L mCRPC (combination therapy), M1 mCRPC (combination therapy)	Phase III www.janssen.com
NT-17 (efineptakin alfa)	NeoImmuneTech Rockville, MD	gastric/gastroesophageal junction adenocarcinoma (combination therapy)	Phase II www.neoimmunetech.com
Nubeqa® darolutamide	Bayer Pharmaceuticals Whippany, NJ	mHSPC, prostate cancer adjuvant	Phase III www.pharma.bayer.com
NUC-1031 (fosgemcitabine palabenamide) ORPHAN DRUG	NuCana Newton, MA	biliary tract cancer	Phase III www.nucana.com
OBI-3424 (cytotoxic prodrug) ORPHAN DRUG	OBI Pharma San Diego, CA	liver cancer, CRPC	Phase I/II www.obipharma.com
OBT076 (antibody-drug conjugate)	Oxford BioTherapeutics San Jose, CA	HER2- breast cancer	Phase I www.oxfordbiotherapeutics.com
ONA-XR (onapristone ER) (progesterone receptor antagonist)	Context Therapeutics Philadelphia, PA	1L+ metastatic breast cancer	Phase II www.contexttherapeutics.com
ONC-392 (CTLA4 inhibitor)	OncoC4 Rockville, MD	NSCLC	Phase I www.oncoc4.com
Onivyde® irinotecan liposome injection	Ipsen Cambridge, MA	SCLC (Fast Track)	Phase III www.ipsen.com

Cancer Product Name	Sponsor	Indication	Development Status
onvansertib (PLK1 inhibitor)	Cardiff Oncology San Diego, CA	mCRPC	Phase II www.cardiffoncology.com
OP-1250 (ER antagonist/SERD)	Olema Pharmaceuticals San Francisco, CA	HR+ HER2- breast cancer	Phase I/II www.olema.com
Opdivo® nivolumab	Bristol-Myers Squibb Princeton, NJ	1L liver cancer, adjuvant liver cancer, neoadjuvant NSCLC, unresectable NSCLC, adjuvant kidney cancer, adjuvant gastric cancer, mCRPC, peri-adjuvant NSCLC, neoadjuvant ER+ HER2- breast cancer	Phase III www.bms.com
		neoadjuvant ER+ HER2- breast cancer (+CDK4/6 inhibitor), advanced kidney cancer (combination therapy)	Phase II www.bms.com
Opdivo® + bempegaldesleukin nivolumab + bempegaldesleukin	Bristol-Myers Squibb Princeton, NJ Nektar Therapeutics San Francisco, CA	1L kidney cancer	Phase III www.bms.com www.nektar.com
Opdivo® + Yervoy® nivolumab + ipilimumab	Bristol-Myers Squibb Princeton, NJ	1L liver cancer, intermediate liver cancer, adjuvant kidney cancer, EGFR-mutant NSCLC, unresectable NSCLC, 1L gastric cancer, metastatic kidney cancer (+cabozantinib)	Phase III www.bms.com
		mCRPC	Phase II www.bms.com

Cancer Product Name	Sponsor	Indication	Development Status
ORIC-101 (glucocorticoid receptor antagonist)	ORIC Pharmaceuticals South San Francisco, CA	prostate cancer (combination therapy)	Phase I www.oricpharma.com
ORIN1001 (IRE1a inhibitor)	Orinove Newbury Park, CA	metastatic breast cancer (Fast Track)	Phase I/II www.orinove.com
OSE-2101 (cancer vaccine) ORPHAN DRUG	OSE Immunotherapeutics Nantes, France	NSCLC	Phase III www.ose-immuno.com
OTS167 (MELK inhibitor)	OncoTherapy Science Kawasaki, Japan	breast cancer, TNBC	Phase I www.oncotherapy.co.jp
pamiparib (BGB-290) (PARP inhibitor)	BeiGene Cambridge, MA	1L platinum-sensitive gastric cancer (maintenance)	Phase II www.beigene.com
PCUR-101 (multi-protein inhibitor)	Pellficure Pharmaceuticals San Diego, CA	mCRPC (combination therapy)	Phase I
PDS0101 (cancer immunotherapy)	PDS Biotechnology Florham Park, NJ	stage IIb-IVa cervical cancer	Phase II www.pdsbiotech.com
pegargiminase (ADI-PEG-20) ORPHAN DRUG	Polaris Pharmaceuticals San Diego, CA	liver cancer	Phase II www.polarispharma.com
pelareorep (immuno-oncolytic virus)	Oncolytics Biotech Calgary, Canada	HR+ HER2- breast cancer	Phase II www.oncolyticsbiotech.com

Cancer Product Name	Sponsor	Indication	Development Status
PEN-221 (SSTR2 modulator)	Tarveda Therapeutics Watertown, MA	SCLC	Phase II www.tarvedatx.com
pepinemab (anti-SEMA4D mAb)	Vaccinex Rochester, NY	NSCLC (combination therapy)	Phase II www.vaccinex.com
Pexa-Vec (pexastimogene devacirepvec) (oncolytic vaccinia poxvirus)	SillaJen Biotherapeutics Busan, South Korea	kidney cancer (combination therapy)	Phase I/II www.sillajen.com
PF-06873600 (ebvaciclib) (CDK-2/4/6 inhibitor)	Pfizer New York, NY	metastatic breast cancer	Phase I www.pfizer.com
PF-07104091 (CDK2 inhibitor)	Pfizer New York, NY	metastatic breast cancer	Phase I www.pfizer.com
PF-07220060 (CDK4 inhibitor)	Pfizer New York, NY	metastatic breast cancer	Phase I www.pfizer.com
PF-07248144 (KAT6A epigenetic modifier)	Pfizer New York, NY	metastatic breast cancer	Phase I www.pfizer.com
Piqray [®] alpelisib	Novartis East Hanover, NJ	HER2+ breast cancer, TNBC	Phase III www.novartis.com

Cancer Product Name	Sponsor	Indication	Development Status
plinabulin	BeyondSpring Pharmaceuticals New York, NY	2L/3L NSCLC (+docetaxel)	Phase III www.beyongspringpharma.com
		2L/3L NSCLC (combination therapy), SCLC (combination therapy)	Phase I www.beyondspringpharma.com
PLX2853 (BET inhibitor)	Daiichi Sankyo Basking Ridge, NJ Plexxikon Berkeley, CA	mCRPC	Phase I www.daiichi.com www.plexxikon.com
PLX9486 (KIT inhibitor)	Cogent Biosciences Cambridge, MA Plexxikon Berkeley, CA	gastrointestinal stromal tumors	Phase I www.cogentbio.co www.plexxikon.com
PMD-026 (RSK inhibitor)	Phoenix Molecular Designs San Diego, CA	metastatic breast cancer, YNBC	Phase I www.phoenixmd.ca
PNT2002 (PSMA radio-ligand therapeutic)	POINT Biopharma USA Indianapolis, IN	mCRPC	Phase III www.pointbiopharma.com
polyclonal antibody stimulator (gastrin inhibitor) ORPHAN DRUG	Cancer Advances Durham, NC	gastric cancer	Phase III www.canceradvances.com
poziotinib (TKI inhibitor)	Spectrum Pharmaceuticals Henderson, NV	EGFR or HER2 exon 20 mutation positive NSCLC (Fast Track)	Phase II www.sppirx.com

Cancer Product Name	Sponsor	Indication	Development Status
P-PSMA-101 (CAR-T cell therapy)	Poseida Therapeutics San Diego, CA	prostate cancer	Phase I www.poseida.com
Provenge® sipuleucel-T	Dendreon Seal Beach, CA	newly-diagnosed prostate cancer	Phase III www.dendreon.com
proxalutamide (GT0918) (androgen receptor antagonist)	Suzhou Kintor Pharmaceutical Jiangsu, China	mCRPC	Phase II www.kintor.com.cn
PSMA TmPSMA-01 (CAR-T cell therapy)	Tmunity Therapeutics Philadelphia, PA	prostate cancer	Phase I www.tmunity.com
PT-112 (apoptosis stimulant)	Phosplatin Therapeutics New York, NY	NSCLC (combination therapy)	Phase I/II www.phosplatin.com
PUR1800 (kinase inhibitor)	Pulmatrix Lexington, MA	lung cancer	Phase I www.pulmatrix.com
PV-10 (rose bengal sodium) ORPHAN DRUG	Provectus Biopharmaceuticals Knoxville, TN	metastatic cancer to the liver (+ checkpoint blockade)	Phase I www.provectusbio.com
PVX-410 (multi-peptide therapeutic cancer vaccine)	OncoPep Boston, MA	TNBC	Phase I completed www.oncopep.com
pyrotinib (EGFR/HER2 inhibitor)	Hengrui USA Princeton, NJ	HER2+ NSCLC	Phase III www.hengruiusa.com

Cancer Product Name	Sponsor	Indication	Development Status
quaratusugene ozeplasmid (GPX-001) (TUS2 nanoparticle gene therapy)	Genprex Austin, TX	NSCLC (combination therapy) (Fast Track)	Phase I/II www.genprex.com
REGN5093 (METxMET bispecific antibody)	Regeneron Pharmaceuticals Tarrytown, NY	MET-altered advanced NSCLC	Phase I www.regeneron.com
REGN5678 (PSMAxCD28 antibody)	Regeneron Pharmaceuticals Tarrytown, NY	prostate cancer	Phase I www.regeneron.com
REIC gene therapy (MTG201) (AAV-based gene therapy) ORPHAN DRUG	Momotaro-Gene Okayama, Japan	malignant pleural mesothelioma, prostate cancer	Phase II www.mt-gene.com
relacorilant (glucocorticoid receptor II antagonist)	Corcept Therapeutics Menlo Park, CA	CRPC (+enzalutamide)	Phase II www.corcept.com
relatlimab (anti-LAG-3 antibody)	Bristol-Myers Squibb Princeton, NJ	liver cancer (+nivolumab), NSCLC (+nivolumab)	Phase II www.bms.com
REM-001 therapy (photodynamic therapy)	Kintara Therapeutics San Diego, CA	cutaneous metastatic breast cancer	Phase II www.kintara.com
reprotrectinib (TPX-0005) (ROS1/TRK inhibitor) ORPHAN DRUG	Turning Point Therapeutics San Diego, CA	ROS1+ advanced NSCLC (Fast Track) (Breakthrough Therapy)	Phase II www.tptherapeutics.com
Retevmo™ selpercatinib	Lilly Indianapolis, IN	1L NSCLC	Phase III www.lilly.com

Cancer Product Name	Sponsor	Indication	Development Status
retifanlimab (anti-PD-1 mAb)	Incyte Wilmington, DE MacroGenics Rockville, MD	NSCLC	Phase III www.incyte.com www.macrogenics.com
RG6114 (GDC-0077) (PI3K inhibitor)	Roche/Genentech South San Francisco, CA	1L HR+ metastatic breast cancer	Phase III www.roche.com
RG6115 (RO7119929) (TLR7 agonist)	Roche/Genentech South San Francisco, CA	liver cancer	Phase I www.roche.com
RG6171 (GDC-9545) (giredestrant) (SERD)	Roche/Genentech South San Francisco, CA	ER+ HER2- metastatic breast cancer	Phase III www.roche.com
		ER+ breast cancer (neoadjuvant), 2L/3L ER+ HER2-negative breast cancer	Phase II www.roche.com
		1L ER+ HER2- breast cancer	Phase I www.roche.com
RG6194 (BTRC4017A) (HER2xCD3 bispecific antibody)	Roche/Genentech South San Francisco, CA	breast cancer	Phase I www.roche.com
RG7440 (ipatasertib) (pan-Akt inhibitor)	Roche/Genentech South San Francisco, CA	1L CRPC (combination therapy), 1L HR+ metastatic breast cancer (combination therapy)	Phase III www.roche.com
		mCRPC (+rucaparib), untreated prostate cancer	Phase I www.roche.com

Cancer Product Name	Sponsor	Indication	Development Status
RGX-104 (LXR agonist)	Rgenix New York, NY	1L non-squamous NSCLC, 2L SCLC (combination therapy)	Phase I/II www.rgenix.com
RGX-202 (cancer metabolism therapeutic)	Rgenix New York, NY	gastric cancer (combination therapy)	Phase I www.rgenix.com
rintatolimod (RNA therapeutic)	AIM ImmunoTech Ocala, FL	early stage prostate cancer, TNBC	Phase II www.aimimmuno.com
		early-stage TNBC	Phase I www.aimimmuno.com
rintodestrant (G1T-48) (SERD)	G1 Therapeutics Research Triangle Park, NC	ER+ HER2- breast cancer (+palbociclib)	Phase II www.g1therapeutics.com
		ER+ HER2- breast cancer	Phase I www.g1therapeutics.com
ripretinib (KIT/PDGFRα inhibitor)	Deciphera Pharmaceuticals Waltham, MA	2L gastrointestinal stomal tumors	Phase III www.deciphera.com
rivoceranib (apatinib) (tyrosine kinase inhibitor) ORPHAN DRUG	Elevar Therapeutics Salt Lake City, UT	3L/4L gastric cancer, 1L liver cancer (combination therapy)	Phase III www.elevartherapeutics.com
RMC-4630 (PTP-SHP2 inhibitor)	Revolution Medicines Redwood City, CA	EGFR+ NSCLC	Phase I/II www.revmed.com

Cancer Product Name	Sponsor	Indication	Development Status
Rozlytrek® entrectinib	Roche/Genentech South San Francisco, CA	1L NSCLC	Phase III www.roche.com
RPTR-168 (multi-targeted T cell therapy)	Repertoire Immune Medicines Cambridge, MA	cervical cancer	Phase I www.repertoire.com
RRx-001 (CD47-SIRPα inhibitor) ORPHAN DRUG	EpigentRx La Jolla, CA	SCLC	Phase III www.epigentrx.com
RTX-321 (red blood cell therapy)	Rubius Therapeutics Cambridge, MA	HPV-16-positive cervical cancer	Phase I www.rubiustx.com
Rubraca® rucaparib	Clovis Oncology Boulder, CO	CRPC w/gene alterations	Phase III www.clovisoncology.com
RV001V (RhoC peptide vaccine)	RhoVac Lund, Sweden	prostate cancer (FastTrack)	Phase II www.rhovac.com
Rybrevant® amivantamab	Janssen Research & Development Raritan, NJ	1L NSCLC (combination therapy)	Phase III www.janssen.com
sapacitabine (DNA damage respiratory inhibitor)	Cyclacel Pharmaceuticals Berkeley Heights, NJ	BRCA-mutant breast cancer	Phase I/II www.cyclacel.com

Cancer Product Name	Sponsor	Indication	Development Status
SAR439859 (amcenestrant) (SERD)	Sanofi Bridgewater, NJ	1L metastatic breast cancer (combination therapy)	Phase III www.sanofi.com
		2/3L metastatic breast cancer, early breast cancer	Phase II www.sanofi.com
sasanlimab (PF-06801591) (anti-PD-1)	Pfizer New York, NY	NSCLC (combination therapy)	Phase I/II www.pfizer.com
SB8 (bevacizumab biosimilar)	Samsung Bioepis Incheon, Korea	NSCLC	application submitted www.samsungbioepis.com
selinexor (CRM1 inhibitor)	Karyopharm Therapeutics Newton, MA	NSCLC (+ docetaxel)	Phase I www.karyopharm.com
silmitasertib (CX-4945) (CK2 inhibitor) ORPHAN DRUG	Senhwa Biosciences Taipei, Taiwan	cholangiocarcinoma	Phase II www.senhwabiosciences.com
sintilimab (PD-1 inhibitor)	Innovent Biologics Suzhou, China Lilly Indianapolis, IN	1L nonsquamous NSCLC	application submitted www.lilly.com
sitravatinib (RTK inhibitor)	Mirati Therapeutics San Diego, CA	2L/3L NSCLC (+PD-1)	Phase III www.mirati.com
		clear cell kidney cancer (combination therapy)	Phase I/II www.mirati.com

Cancer Product Name	Sponsor	Indication	Development Status
SLATE (neoantigen-based immunotherapy)	Gritstone bio Emeryville, CA	NSCLC	Phase I/II www.gritstonebio.com
SM-88 (racemetyrosine) (cancer metabolism-based therapeutic)	Tyme Technologies Bedminster, NJ	prostate cancer	Phase II completed www.tymeinc.com
SNK01 (autologous NK cell therapy)	NKGen Biotech Santa Ana, CA	NSCLC (+pembrolizumab)	Phase II www.nkgenbiotech.com
Stivarga [®] regorafenib	Bayer Pharmaceutical Whippany, NJ	liver cancer (+pembrolizumab)	Phase II www.bayer.com
STP705 (siRNA therapeutic) ORPHAN DRUG	Sirnaomics Gaithersburg, MD	liver cancer	Phase I www.sirnaomics.com
SV-BR-1-GM cancer vaccine (allogeneic genetically-engineered cell vaccine)	BriaCell Therapeutics Berkeley, CA	breast cancer (combination therapy)	Phase I/II www.briacell.com
SY-5609 (CDK7 inhibitor)	Syros Pharmaceuticals Cambridge, MA	HR+ HER2- breast cancer	Phase I www.syros.com
SYD985 (trastuzumab duocarmazine)	Byondis Nijmegen, The Netherlands	metastatic breast cancer (Fast Track)	Phase III www.byondis.com
Sym015 (c-MET inhibitor)	Symphogen Ballerup, Denmark	lung cancer	Phase I/II www.symphogen.com

Cancer Product Name	Sponsor	Indication	Development Status
Tabrecta™ capmatinib	Novartis East Hanover, NJ	NSCLC (combination therapy)	Phase II www.novartis.com
Taclantis™ paclitaxel injection concentrate for suspension	Sun Pharma Advanced Research Mumbai, India	breast cancer	application submitted www.sparc.life
TAEK-VAC-HerBy (cancer vaccine)	Bavarian Nordic Morrisville, NC	HER2+ breast cancer, HER2+ gastric cancer	Phase I/II www.bavarian-nordic.com
Tagrisso® osimertinib	AstraZeneca Wilmington, DE	stage 3 EGFR-mutant NSCLC, 1L advanced EGFR-mutant NSCLC (combination therapy), stage 2/3 resectable EGFR-mutant NSCLC	Phase III www.astrazeneca.com
		-----	-----
		post-1L EGFR-mutant NSCLC, EGFR-mutant NSCLC (+savolitinib)	Phase II www.astrazeneca.com
-----	-----	-----	-----
		EGFR-mutant NSCLC (combination therapy)	Phase I www.astrazeneca.com
Talzenna® talazoparib	Pfizer New York, NY	1L metastatic castration-resistant prostate cancer (+enzalutamide)	Phase III www.pfizer.com
		-----	-----
		2L mCRPC, germline BRCA-mutant locally advanced TNBC	Phase II www.pfizer.com
tarloxotinib (pan-HER inhibitor)	Rain Therapeutics Newark, CA	NSCLC	Phase II www.rainthera.com

Cancer Product Name	Sponsor	Indication	Development Status
TAS-120 (futibatinib) (FGFR inhibitor) ORPHAN DRUG	Taiho Oncology Princeton, NJ	cholangiocarcinoma (Breakthrough Therapy)	Phase III www.taihooncology.com
		breast cancer	Phase II www.taihooncology.com
TAS-3681 (androgen receptor antagonist)	Taiho Oncology Princeton, NJ	CRPC	Phase I www.taihooncology.com
TAVO (tavokinogene telseplasmid) (IL-12 gene therapy)	OncoSec Medical San Diego, CA	TNBC (+pembrolizumab)	Phase II www.oncosec.com
TAVT-45 (abiraterone acetate enhanced formulation)	Tavanta Therapeutics Media, PA	prostate cancer	Phase III www.tavanta.com
Tazverik™ tazemetostat	Epizyme Cambridge, MA	CRPC	Phase I/II www.epizyme.com
TC-210 (T-cell therapy) ORPHAN DRUG	TCR2 Therapeutics Cambridge, MA	cholangiosarcoma, NSCLC	Phase I/II www.tcr2.com
TEC-100 (TATE) (hypoxia-activating agent)	Teclison Montclair, NJ	liver cancer (combination therapy)	Phase II www.teclison.com

Cancer Product Name	Sponsor	Indication	Development Status
Tecentriq® atezolizumab	Roche/Genentech South San Francisco, CA	adjuvant NSCLC, neoadjuvant/ adjuvant TNBC, 1L TNBC, kidney cancer adjuvant, liver cancer adjuvant, 2L NSCLC, SC-NSCLC	Phase III www.roche.com
		1L extensive-stage SCLC	Phase I www.roche.com
telaglenastat (glutaminase inhibitor)	Calithera Biosciences South San Francisco, CA	NSCLC	Phase II www.calithera.com
telisotuzumab vedotin (ABBV-399) (antibody-drug conjugate)	AbbVie North Chicago, IL	cMet+ NSCLC	Phase II www.abbvie.com
Telomelysin® suratadenoturev	Oncolys BioPharma Edison, NJ	gastric cancer	Phase II www.oncolys.com
		liver cancer	Phase I www.oncolys.com
Tepmetko® tepotinib	EMD Serono Rockland, MA	EGFR-mutant NSCLC (MET amplified)	Phase II www.emdserono.com
ThermoDox® doxorubicin liposomal ORPHAN DRUG	Celsion Lawrenceville, NJ	primary liver cancer (Fast Track)	Phase III www.celsion.com

Cancer Product Name	Sponsor	Indication	Development Status
Tibsovo® ivosidenib ORPHAN DRUG	Servier Boston, MA	2L IDH1-mutant cholangiocarcinoma (Fast Track)	application submitted www.servier.us
tidutamab (XmAb-18087) (SSTR2xCD3 bispecific antibody)	Xencor Monrovia, CA	gastrointestinal stromal tumors	Phase I www.xencor.com
tiragolumab (RG6058) (anti-TIGIT mAb)	Roche/Genentech South San Francisco, CA	1L SCLC (combination therapy), 1L PD-L1+ NSCLC (+atezolizumab) (Breakthrough Therapy), stage III unresectable NSCLC (+atezolizumab)	Phase III www.roche.com
		NSCLC (+atezolizumab), cervical cancer (+atezolizumab) 1L non-squamous NSCLC (combination therapy)	Phase II www.roche.com
tislelizumab (VDT482) (anti-PD-1 mAb) ORPHAN DRUG	BeiGene Cambridge, MA Novartis East Hanover, NJ	1L gastric cancer (combination therapy), liver cancer, NSCLC	Phase III www.beigene.co www.novartis.com
tisotumab vedotin (antibody-drug conjugate)	Genmab Plainsboro, NJ Seagen Bothell, WA	2L/3L cervical cancer (monotherapy)	application submitted www.genmab.com www.seagen.com
		1L/2L cervical cancer (combination therapy)	Phase II www.genmab.com www.seagen.com

Cancer Product Name	Sponsor	Indication	Development Status
TNB-585 (PSMAxCD3 bispecific antibody)	TeneoBio Newark, CA	mCRPC	Phase I www.teneobio.com
TnMUC-1 (TmTN-MUC-01 CAR-T cell therapy)	Tmunity Therapeutics Philadelphia, PA	NSCLC, TNBC	Phase I www.tmunity.com
tomivosertib (eFT-508) (MNK1/2 inhibitor)	Effector Therapeutics San Diego, CA	1L NSCLC (+pembrolizumab) metastatic breast cancer (combination therapy)	Phase II www.effector.com
TOOKAD® padeliporfin	Steba Biotech Luxembourg City, Luxembourg	intermediate-risk prostate cancer	Phase II www.stebabiotech.com
TPIV200 (peptide dendritic vaccine)	Marker Therapeutics Houston, TX	TNBC	Phase II www.markertherapeutics.com
TPX-0131 (ALK inhibitor)	Turning Point Therapeutics San Diego, CA	NSCLC	Phase I www.tptherapeutics.com
TRC102 (DNA repair inhibitor)	TRACON Pharmaceuticals San Diego, CA	mesothelioma	Phase II www.traconpharma.com
		lung cancer	Phase I www.traconpharma.com

Cancer Product Name	Sponsor	Indication	Development Status
Trodelvy™ sacituzumab govitecan-hziy	Gilead Sciences Foster City, CA	HR+ HER2- metastatic breast cancer	Phase III www.gilead.com
		1L metastatic TNBC, TNBC (combination therapy), metastatic NSCLC	Phase I/II www.gilead.com
TT-00420 (multiple kinase inhibitor)	TransThera Biosciences Nanjing, China	TNBC	Phase I
tucidinostat (HBI-8000) (HDAC inhibitor)	HUYA Bioscience San Diego, CA	NSCLC, kidney cancer	Phase I/II www.huyabio.com
Tukysa® tucatinib	Merck Kenilworth, NJ Seagen Bothell, WA	high-risk HER2+ metastatic breast cancer	Phase III www.seagen.com
		1L HER2+ gastric cancer	Phase I www.seagen.com
tusamitamab ravtansine (anti-CEACAM5 ADC)	Sanofi Bridgewater, NJ	2L/3L NSCLC	Phase III www.sanofi.com
		2L/3L NSCLC (+ramucirumab), 1L NSCLC (+pembrolizumab)	Phase II www.sanofi.com

Cancer Product Name	Sponsor	Indication	Development Status
U3-1402 (patritumab derutecan) (anti-HER3 antibody-drug conjugate)	Daiichi Sankyo Basking Ridge, NJ	EGFR-mutant NSCLC	Phase II www.dsi.com
		breast cancer, EGFR-mutant NSCLC, NSCLC	Phase I www.dsi.com
upifitamab rilsodotin (antibody-drug conjugate)	Mersana Therapeutics Cambridge, MA	NSCLC	Phase I www.mersana.com
V937 (oncolytic virus vaccine)	Merck Kenilworth, NJ	breast cancer	Phase II www.merck.com
VAC2 (dendritic cell vaccine)	Lineage Cell Therapeutics Carlsbad, CA	NSCLC	Phase I www.lineagecell.com
veliparib (ABT-888) (PARP inhibitor) ORPHAN DRUG	AbbVie North Chicago, IL	BRCA-associated breast cancer, NSCLC	Phase III www.abbvie.com
Venclexta [®] venetoclax	AbbVie North Chicago, IL Roche/Genentech South San Francisco, CA	2L HR+ breast cancer	Phase II www.abbvie.com www.roche.com
VERU-100 (long-acting GnRH antagonist depot)	Veru Miami, FL	advanced prostate cancer	Phase I/II www.verupharma.com
VERU-111 (sabizabulin) (tubulin polymerization inhibitor)	Veru Miami, FL	mCRPC	Phase III www.verupharma.com

Cancer Product Name	Sponsor	Indication	Development Status
Verzenio® abemaciclib	Eli Lilly Indianapolis, IN	breast cancer (adjuvant therapy)	application submitted www.lilly.com
		prostate cancer	Phase II www.lilly.com
viagenpumatu cel-L (HS-110) (allogeneic tumor cell vaccine)	Heat Biologics Morrisville, NC	NSCLC	Phase II www.heatbio.com
Vigil™ (genetically-modified autologous tumor cell vaccine and bi-shRNAfurin)	Gradalis Dallas, TX	breast cancer (IO combination)	Phase I www.gradalisinc.com
VIMO-001 (alpha-TEA) (alpha-tocopherolxyacetic acid)	Veana Therapeutics Portland, OR	breast cancer	Phase I www.veana-therapeutics.com
vorolanib (VEGFR/PDGFR inhibitor)	Xcovery Holdings Palm Beach Gardens, FL	NSCLC, SCLC	Phase II www.xcovery.com
Voyager-V1 (oncolytic virus)	Vyriad Rochester, MN	liver cancer (+cemiplimab), NSCLC (+cemiplimab), N SCLC (+pembrolizumab)	Phase II www.vyriad.com
VS-6766 (RAF/MEK inhibitor)	Verastem Oncology Boston, MA	KRAS-mutant NSCLC (monotherapy and +defactinib)	Phase II www.verastem.com
vusolimogene oderparepvec (RP1) (oncolytic immunotherapy)	Replimune Woburn, MA	NSCLC (anti-PD1 failed)	Phase I www.replimune.com

Cancer Product Name	Sponsor	Indication	Development Status
xentuzumab (BI 836845) (IGF-1/2 inhibitor)	Boehringer Ingelheim Ridgefield, CT	HR+ HER2- metastatic breast cancer	Phase II www.boehringer-ingelheim.com
XMT-1592 (antibody-drug conjugate)	Mersana Therapeutics Cambridge, MA	NSCLC	Phase I www.mersana.com
Xtandi® enzalutamide	Astellas Pharma Northbrook, IL Pfizer New York, NY	non-metastatic high-risk castration sensitive prostate cancer	Phase III www.astellas.com www.pfizer.com
Yeliva® opaganib ORPHAN DRUG	RedHill Biopharma Raleigh, NC	cholangiocarcinoma	Phase II www.redhillbio.com
YIV-906 (Chinese herbal botanical formulation) ORPHAN DRUG	Yiviva New York, NY	advanced liver cancer	Phase II www.yiviva.com
zalifrelimab (AGEN1884) (anti-CTLA-4mAb)	Agenus Lexington, MA	cervical cancer (Fast Track)	Phase II www.agenisbio.com

Cancer Product Name	Sponsor	Indication	Development Status
zanidatamab (ZW25) (HER2 x HER2 bispecific antibody) ORPHAN DRUG	Zymeworks Seattle, WA	HER2-amplified biliary tract cancer (Breakthrough Therapy) (Fast Track)	Phase III www.zymeworks.com
		HER2-positive/HR-positive advanced breast cancer, HER2-expressing gastroesophageal adenocarcinoma (Fast Track)	Phase II www.zymeworks.com
		biliary tract cancer (monotherapy and combination therapy)	Phase I www.zymeworks.com
Zejula [®] niraparib	GlaxoSmithKline Research Triangle Park, NC	1L NSCLC maintenance (+pembrolizumab)	Phase III www.gsk.com
ZEN-3694 (BET inhibitor)	Zenith Epigenetics San Francisco, CA	prostate cancer (combination therapy), TNBC (combination therapy)	Phase II www.zenithepigenetics.com
zimberelimab (GS-0122) (PD-1 mAb)	Arcus Biosciences Hayward, CA Gilead Sciences Foster City, CA	NSCLC	Phase III www.gilead.com
ZN-c5 (SERD)	Zentalis Pharmaceuticals New York, NY	breast cancer	Phase I/II www.zentalis.com
ZN-e4 (EGFR antagonist)	Zentalis Pharmaceuticals New York, NY	NSCLC	Phase I/II www.zentalis.com

Cancer
Product Name

Sponsor

Indication

Development Status

zolbetuximab
(anti-claudin 18.2 mAb)
ORPHAN DRUG

Astellas Pharma
Northbrook, IL

gastric/gastroesophageal junction
adenocarcinoma

Phase III
www.astellas.com

Chronic Kidney Disease
Product Name

Sponsor

Indication

Development Status

AZD2373
(RNAi)

AstraZeneca
Wilmington, DE

chronic kidney disease

Phase I
www.astrazeneca.com

AZD5718
(5-lipoxygenase activating protein
inhibitor)

AstraZeneca
Wilmington, DE

chronic kidney disease

Phase II
www.astrazeneca.com

BAY2327949
(vasopressin V1a receptor antagonist)

Bayer Pharmaceutical
Whippany, NJ

chronic kidney disease

Phase I
www.pharma.bayer.com

BI 685509

Boehringer Ingelheim
Ridgefield, CT

chronic kidney disease,
diabetic kidney disease

Phase II
www.boehringer-ingelheim.com

cotadutide (MEDI0382)
(GLP-1/glucagon receptor
dual agonist)

AstraZeneca
Wilmington, DE

diabetic kidney disease

Phase II
www.astrazeneca.com

DM199
(recombinant human kallikren-1)

DiaMedica Therapeutics
Minneapolis, MN

chronic kidney disease in African
Americans, diabetic kidney disease

Phase II
www.diamedica.com

Chronic Kidney Disease

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
Farxiga [®] dapagliflozin	AstraZeneca Wilmington, DE	renal outcomes and cardiovascular mortality in patients with CKD	Phase III www.astrazeneca.com
finerenone (mineralocorticoid receptor antagonist)	Bayer Pharmaceuticals Whippany, NJ	diabetic kidney disease (Fast Track)	application submitted www.bayer.pharma.com
GSK1278863 (daprodustat) (prolyl hydroxylase inhibitor)	GlaxoSmithKline Research Triangle Park, NC	chronic kidney disease anemia	Phase III www.gsk.com
Jardiance [®] empagliflozin	Boehringer Ingelheim Ridgefield, CT Lilly Indianapolis, IN	chronic kidney disease (Fast Track)	Phase III www.boehringer-ingelheim.com www.lilly.com
KBP-5074 (mineralocorticoid receptor antagonist)	KBP Biosciences Princeton, NJ	kidney protection	Phase II www.kbpbio.com
LMB763 (LXR agonist)	Novartis East Hanover, NJ	diabetic kidney disease	Phase II www.novartis.com
MEDI3506 (IL-33 mAb)	AstraZeneca Wilmington, DE	diabetic kidney disease	Phase II www.astrazeneca.com
MEDI8367 (avb8)	AstraZeneca Wilmington, DE	chronic kidney disease	Phase I www.astrazeneca.com
MK-2060 (blood coagulation modulator)	Merck Whitehouse Station, NJ	chronic kidney failure	Phase I www.merck.com

**Chronic Kidney Disease
Product Name**

Sponsor

Indication

Development Status

REACT (autologous cell therapy)	ProKidney Winston-Salem, NC	diabetic kidney disease	Phase II www.prokidney.com
roxadustat	AstraZeneca Wilmington, DE Fibrogen San Francisco, CA	anemia in chronic kidney disease	application submitted www.astrazeneca.com www.fibrogen.com
runcacguat (sGC activator)	Bayer Pharmaceutical Whippany, NJ	chronic kidney disease	Phase II www.pharma.bayer.com
selonsertib (GS-4997) (ASK1 inhibitor)	Gilead Sciences Foster City, CA	diabetic kidney disease	Phase II www.gilead.com
SOANZ (diuretic)	Sarfez Pharmaceuticals Vienna, VA	chronic kidney disease	application submitted www.sarfezpharma.com
TRC101 (veverimer) (non-absorbed polymer)	Tricida South San Francisco, CA	metabolic acidosis in chronic kidney disease	Phase III www.tricida.com
vadadustat (HIF-PH inhibitor)	Akebia Therapeutics Cambridge, MA	chronic kidney disease anemia	application submitted www.akebia.com
verinurad (SLC22A12 protein inhibitor)	AstraZeneca Wilmington, DE	chronic kidney disease	Phase II www.astrazeneca.com

Chronic Obstructive Pulmonary Disease

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
acumapimod (oral p38 MAP kinase inhibitor)	Mereo BioPharma London, United Kingdom	acute exacerbations of chronic obstructive pulmonary disease (COPD)	Phase II completed www.mereobiopharma.com
BI 1323495 (leukocyte protease inhibitor)	Boehringer Ingelheim Pharmaceuticals Ridgefield, CT	COPD	Phase I www.boehringer-ingelheim.com
Bio-11006 (myristoylated alanine rich C kinase substrate inhibitor)	BioMarck Pharmaceuticals Research Triangle Park, NC	COPD	Phase II www.biomarck.com
brensocatib (AZD7986) (DPP1 inhibitor)	AstraZeneca Wilmington, DE	COPD	Phase II www.astrazeneca.com
CHF 5993 (beclometasone/formoterol/ glycopyrrolate combination)	Chiesi USA Cary, NC	COPD	Phase III www.chiesi.com
CHF6001 (PDE4 inhibitor)	Chiesi USA Cary, NC	COPD	Phase II www.chiesi.com
Dupixent [®] dupilumab	Regeneron Pharmaceuticals Tarrytown, NY Sanofi US Bridgewater, NJ	COPD	Phase III www.regeneron.com www.sanofi.com
ensifentrine (PDE 3/4 inhibitor)	Verona Pharma Raleigh, NC	COPD	Phase III www.veronapharma.com

Chronic Obstructive Pulmonary Disease

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
Fasenra® benralizumab	AstraZeneca Wilmington, DE	COPD	Phase III www.astrazeneca.com
GSK3923868 (PI4K beta inhibitor)	GlaxoSmithKline Research Triangle Park, NC	viral COPD exacerbations	Phase I www.gsk.com
itepekimab (SAR440340/REGN3500) (anti-IL33 mAb)	Regeneron Pharmaceuticals Tarrytown, NY Sanofi US Bridgewater, NJ	COPD	Phase III www.regeneron.com www.sanofi.com
lemborexant (E2006) (orexin receptor antagonist)	Eisai Woodfield, NJ	COPD	Phase I www.eisai.com
MEDI3506 (IL-33 mAb)	AstraZeneca Wilmington, DE	COPD	Phase II www.astrazeneca.com
navafenterol (AZD8871) (muscarinic antagonist/ beta 2 agonist)	AstraZeneca Wilmington, DE	COPD	Phase II www.astrazeneca.com
Nucala® mepolizumab	GlaxoSmithKline Research Triangle Park, NC	COPD	Phase III www.gsk.com
PUL-042 (innate immune system stimulator)	Pulmotect Houston, TX	COPD exacerbations	Phase II www.pulmotect.com
PUR1800 (NSKI inhibitor)	Pulmatrix Lexington, MA	COPD	Phase I www.pulmatrix.com

Chronic Obstructive Pulmonary Disease

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
QBW251 (icentricaftor) (CFTR potentiator)	Novartis Pharmaceuticals East Hanover, NJ	COPD	Phase II www.novartis.com
SelK2 (PSGL-1 inhibitor)	Tetherex Pharmaceuticals Oklahoma City, OK	COPD	Phase II www.therex.com
tezepelumab (TSLP inhibitor)	Amgen Thousand Oaks, CA AstraZeneca Wilmington, DE	COPD	Phase II www.amgen.com www.astrazeneca.com
Zofin™ nanoparticle based therapeutic	Organicell Miami, FL	COPD	Phase I/II www.organicell.com

Coronary Artery Disease

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
AZD5718 (5-lipoxygenase activating protein inhibitor)	AstraZeneca Wilmington, DE	coronary artery disease	Phase II www.astrazeneca.com
CVBT-141 (fibroblast growth factor 1)	Venturis Therapeutics Dallas, TX	coronary artery disease	Phase II www.venturistherapeutics.com
IMB-1018972 (ninerafaxstat) (partial fatty acid oxidation inhibitor)	Imbria Pharmaceuticals Boston, MA	coronary artery disease	Phase II www.imbria.com
MEDI5884 (endothelial lipase-neutralising mAb)	AstraZeneca Wilmington, DE	coronary artery disease	Phase II www.astrazeneca.com

Coronary Artery Disease
Product Name

Sponsor

Indication

Development Status

RUC-4 (zalunfiban)
(GPIIb-IIIa antagonist)

CeleCor Therapeutics
Del Mar, CA

coronary artery disease

Phase II
www.celecor.com

ziltivekimab
(anti-IL-6 mAb)

Novo Nordisk
Plainsboro, NJ

reduce cardiovascular risk in chronic
kidney disease

Phase II
www.novonordisk.com

Diabetes, Type 2
Product Name

Sponsor

Indication

Development Status

AER-501
(mist inhaled insulin)

Aerami Therapeutics
Durham, NC

type 2 diabetes

Phase I/II completed
www.aerami.com

AID
(automated insulin
delivery system)

Lilly
Indianapolis, IN

diabetes

Phase II
www.lilly.com

ANJ900
(metformin delayed-release)

Anji Pharma
Cambridge, MA

type 2 diabetes

Phase II
www.anjipharma.com

bexagliflozin
(SGLT2 inhibitor)

Theracos
Marlborough, MA

type 2 diabetes

Phase III
www.theracos.com

BI 456906
(GLP-1/glucagon agonist)

Boehringer Ingelheim
Ridgefield, CT

type 2 diabetes

Phase II
www.boehringer-ingelheim.com

BTI-320
(alpha glucosidase inhibitor)

Boston Therapeutics
Lawrence, MA

type 2 diabetes

Phase II
www.bostonti.com

Diabetes, Type 2

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
BTI-410 (human proislet peptide)	Boston Therapeutics Lawrence, MA	type 1 diabetes, type 2 diabetes	Phase I www.bostonti.com
Bydureon® BCise exenatide extended-release (autoinjector)	AstraZeneca Wilmington, DE	type 2 diabetes (adolescents)	Phase III www.astrazeneca.com
connected care pre-filled insulin pen	Lilly Indianapolis, IN	diabetes	application submitted www.lilly.com
cotadutide (MEDI0382) (GLP-1/glucagon receptor dual agonist)	AstraZeneca Wilmington, DE	type 2 diabetes	Phase II www.astrazeneca.com
CS02 (R-verapamil)	Center Laboratories Taipei, Taiwan	type 2 diabetes	Phase II www.centerlab.com.tw/en
CT-388 (GIP/GLP-1 receptor modulator)	Carmot Therapeutics Berkeley, CA	type 2 diabetes	Phase I www.carmot-therapeutics.us
CT-868 (GIP/GLP-1 receptor modulator)	Carmot Therapeutics Berkeley, CA	type 2 diabetes	Phase I www.carmot-therapeutics.us
DA-1241 (GPR119 protein agonist)	Dong-A ST Seoul, South Korea	type 2 diabetes	Phase I completed www.donga-st.com
danuglipron (PF-06882961) (GLP-1R agonist)	Pfizer New York, NY	type 2 diabetes	Phase II www.pfizer.com

Diabetes, Type 2 Product Name	Sponsor	Indication	Development Status
diabetes therapeutic	Lilly Indianapolis, IN	diabetes	Phase I www.lilly.com
epeleton (DS102) (5-lipoxygenase inhibitor)	Afimmune Dublin, Ireland	type 2 diabetes and hypertriglyceridemia	Phase II www.afimmune.com
Farxiga [®] dapagliflozin	AstraZeneca Wilmington, DE	type 2 diabetes (pediatric)	Phase III www.astrazeneca.com
GGG tri-agonist (GLP-1/GIP/glucagon)	Lilly Indianapolis, IN	diabetes	Phase I www.lilly.com
GIP/GLP coagonist peptide	Lilly Indianapolis, IN	diabetes	Phase I www.lilly.com
GIP/GLP coagonist peptide II	Lilly Indianapolis, IN	diabetes	Phase I www.lilly.com
GIPR agonist long-acting	Lilly Indianapolis, IN	diabetes	Phase I www.lilly.com
HDV insulin (hepatic-directed vesicles containing insulin)	Diasome Pharmaceuticals Cleveland, OH	type 2 diabetes	Phase II completed www.diasome.com
icosema (LAI287/semaglutide)	Novo Nordisk Plainsboro, NJ	type 2 diabetes	Phase I www.novonordisk.com

Diabetes, Type 2
Product Name

Sponsor

Indication

Development Status

INS068
(insulin degludec)

HengRui USA
Princeton, NJ

type 2 diabetes

Phase II
www.hengruius.com

insulin glargine biosimilar

Gan & Lee Pharmaceuticals
Bridgewater, NJ

type 2 diabetes

Phase III
www.ganlee.us

insulin icodec (LAI287)
(long-acting basal insulin analogue)

Novo Nordisk
Plainsboro, NJ

type 2 diabetes

Phase III
www.novonordisk.com

Invokana[®]
canagliflozin

Janssen
Raritan, NJ

type 2 diabetes (10-18 years of age)

Phase III
www.janssen.com

IONIS-GCGR_{RX}
(glucagon receptor antagonist)

Ionis Pharmaceuticals
Carlsbad, CA

type 2 diabetes

Phase II
www.ioniapharma.com

ITCA 650
(exenatide implant)

Intarcia Therapeutics
Boston, MA

type 2 diabetes (twice yearly dosing)

application submitted
www.intarcia.com

Janumet[®]
sitagliptin and metformin

Merck
Kenilworth, NJ

type 2 diabetes (pediatric)

Phase III completed
www.merck.com

Janumet[®] XR
sitagliptin and metformin
controlled-release

Merck
Kenilworth, NJ

type 2 diabetes (pediatric)

Phase III completed
www.merck.com

Januvia[®]
sitagliptin

Merck
Kenilworth, NJ

type 2 diabetes (pediatric)

Phase III completed
www.merck.com

Diabetes, Type 2

<u>Product Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
Jardiance® empagliflozin	Boehringer Ingelheim Pharmaceuticals Ridgefield, CT Lilly Indianapolis, IN	type 2 diabetes (10-17 years)	Phase III www.boehringer-ingelheim.com www.lilly.com
JTT-251 (PDHK inhibitor)	Akros Pharma Princeton, NJ	type 2 diabetes	Phase I www.akrospharma.com
JTT-662 (SGLT1 inhibitor)	Akros Pharma Princeton, NJ	type 2 diabetes	Phase I www.akrospharma.com
KHK inhibitor	Lilly Indianapolis, IN	diabetes	Phase I www.lilly.com
KHK inhibitor II	Lilly Indianapolis, IN	diabetes	Phase I www.lilly.com
LX2761 (SGLT1 inhibitor)	Lexicon Pharmaceuticals The Woodlands, TX	type 2 diabetes	Phase I completed www.lexpharma.com
LY3209590 (basal insulin-Fc)	Lilly Indianapolis, IN	type 2 diabetes	Phase II www.lilly.com
LY3305677 (oxyntomodulin)	Lilly Indianapolis, IN	type 2 diabetes	Phase I www.lilly.com
LY3437943	Lilly Indianapolis, IN	type 2 diabetes	Phase II www.lilly.com

Diabetes, Type 2
Product Name

Sponsor

Indication

Development Status

LY3457263	Lilly Indianapolis, IN	type 2 diabetes	Phase I www.lilly.com
LY3493269	Lilly Indianapolis, IN	type 2 diabetes	Phase I www.lilly.com
LY3502970 (GLP-1 receptor nonpeptide agonist)	Lilly Indianapolis, IN	diabetes	Phase I www.lilly.com
LYN-045 (weekly dapagliflozin)	Lyndra Therapeutics Watertown, MA	type 2 diabetes	Phase I www.lyndra.com
insulin 965 (NNC02680965) (basal insulin)	Novo Nordisk Plainsboro, NJ	type 2 diabetes	Phase I www.novonordisk.com
DNA immunotherapy (plasmid encoding pre- and pro-insulin)	Novo Nordisk Plainsboro, NJ	diabetes	Phase I www.novonordisk.com
glucose sensitive insulin analogue (once-daily treatment)	Novo Nordisk Plainsboro, NJ	diabetes	Phase I www.novonordisk.com
ideal pump insulin (novel insulin analogue ideal for use in a closed loop pump device as delivery)	Novo Nordisk Plainsboro, NJ	diabetes	Phase I www.novonordisk.com
insulin 147 / PCSK9i (long-acting insulin analogue and PCSK9 inhibitor combination)	Novo Nordisk Plainsboro, NJ	diabetes	Phase I www.novonordisk.com

Diabetes, Type 2 Product Name	Sponsor	Indication	Development Status
Nesina® alogliptin	Takeda Pharmaceuticals Deerfield, IL	type 2 diabetes (pediatric)	Phase III www.takeda.com
Onglyza® saxagliptin	AstraZeneca Wilmington, DE	type 2 diabetes (10-17 years)	Phase III www.astrazeneca.com
OPK88003 (pegapamidultide)	OPKO Health Miami, FL	type 2 diabetes	Phase II www.opko.com
ORMD-0801 (oral insulin)	Oramed Pharmaceuticals New York, NY	type 1 diabetes, type 2 diabetes	Phase III www.oramed.com
ORMD-0901 (exenatide oral)	Oramed Pharmaceuticals New York, NY	type 2 diabetes	Phase I www.oramed.com
OW Sema + GIP (fixed ratio combination formulation of semaglutide + GIP analogue)	Novo Nordisk Plainsboro, NJ	type 2 diabetes	Phase I www.novonordisk.com
Ozempic® semaglutide injection 2.0 mg	Novo Nordisk Plainsboro, NJ	type 2 diabetes	application submitted www.novonordisk.com
PB-119 (exenatide pegylated analogue)	PegBio Suzhou, China	type 2 diabetes	Phase II www.pegbio.com
peptide YY analog agonist	Lilly Indianapolis, IN	diabetes	Phase I www.lilly.com

Diabetes, Type 2
Product Name

Sponsor

Indication

Development Status

PF-07081532
(GLP-1R agonist)

Pfizer
New York, NY

type 2 diabetes

Phase I
www.pfizer.com

REMD-477
(glucagon receptor)

REMD Biotherapeutics
Camarillo, CA

type 2 diabetes

Phase II
www.remdbio.com

Rybelsus®
semaglutide tablets (25 mg/50 mg)

Novo Nordisk
Plainsboro, NJ

type 2 diabetes

Phase III
www.novonordisk.com

Steglatro®
ertugliflozin

Merck
Whitehouse Station, NJ

type 2 diabetes (pediatric)

Phase III
www.merck.com

tirzepatide
(GIP/GLP-1 dual receptor agonist)

Lilly
Indianapolis, IN

type 2 diabetes

Phase III
www.lilly.com

tolimidone
(lyn protein-tyrosine
kinase stimulant)

Melior Pharmaceuticals
Exton, PA

type 2 diabetes

Phase II
www.meliorpharmaceuticals.com

Tradjenta®
linagliptin

Boehringer Ingelheim Pharmaceuticals
Ridgefield, CT
Lilly
Indianapolis, IN

type 2 diabetes (pediatric)

Phase III
www.boehringer-ingelheim.com
www.lilly.com

Trulicity®
dulaglutide

Lilly
Indianapolis, IN

type 2 diabetes (pediatric)

Phase III
www.lilly.com

Diabetes, Type 2
Product Name

Sponsor

Indication

Development Status

TTP273
(oral GLP-1R agonist)

vTv Therapeutics
High Point, NC

type 2 diabetes

Phase II
www.vtvtherapeutics.com

VK0612
(FBPase inhibitor)

Viking Therapeutics
San Diego, CA

type 2 diabetes

Phase II
www.vikingtherapeutics.com

Heart Failure
Drug Name

Sponsor

Indication

Development Phase

aMBMC
(allogeneic mesenchymal bone
marrow cell therapy)

CardioCell
San Diego, CA

chronic heart failure

Phase III
www.stemcardiocyte.com

AMG 594 (CK-136)
(troponin stimulant)

Amgen
Thousand Oaks, CA
Cytokinetics
South San Francisco, CA

heart failure

Phase I
www.amgen.com

APD418
(AdrR antagonist)

Arena Pharmaceuticals
Park City, UT

acute heart failure (Fast Track)

Phase II
www.arenapharm.com

AZD3427
(relaxin ThP)

AstraZeneca
Wilmington, DE

heart failure

Phase I
www.astrazeneca.com

AZD4831
(myeloperoxidase modulator)

AstraZeneca
Wilmington, DE

heart failure with a preserved
ejection fraction

Phase II
www.astrazeneca.com

AZD8601
(VEGF-A)

AstraZeneca
Wilmington, DE

heart failure

Phase II
www.astrazeneca.com

Heart Failure

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
AZD9977 (mineralocorticoid receptor modulator)	AstraZeneca Wilmington, DE	heart failure	Phase I www.astrazeneca.com
BMS-986235 (FPR-2 agonist)	Bristol-Myers Squibb Princeton, NJ	heart failure	Phase I www.bms.com
captisol-enabled furosemide	SQ Innovation Burlington, MA	heart failure	Phase I/II
CardiALLO (mesenchymal stem cell therapy)	BioCardia San Carlos, CA	ischemic heart failure	Phase II www.biocardia.com
CardiAMP (bone marrow cell therapy)	BioCardia San Carlos, CA	ischemic heart failure	Phase III www.biocardia.com
dapansutril (OLT1177) (NLRP3 inflammasome inhibitor)	Olatec Therapeutics New York, NY	heart failure	Phase I www.olatec.com
FA-relaxin (relaxin replacement)	Bristol-Myers Squibb Princeton, NJ	heart failure	Phase II www.bms.com
Farxiga [®] dapagliflozin	AstraZeneca Wilmington, DE	prevention of heart failure and cardiovascular death following a myocardial infarction, worsening heart failure or cardiovascular death in patients with chronic heart failure	Phase III www.astrazeneca.com

Heart Failure

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
finerenone (mineralocorticoid receptor antagonist)	Bayer Pharmaceuticals Whippany, NJ	chronic heart failure	Phase III www.bayer.pharma.com
Furoscix [®] furosemide controlled release	scPharmaceuticals Burlington, MA	heart failure congestion due to fluid overload	Phase III completed www.scpharmaceuticals.com
INL1 (chelating agent)	Innolife Chengdu, China	heart failure with reduced ejection fraction	Phase I www.innolife.com.cn
Invokana [®] canagliflozin	Janssen Research & Development Raritan, NJ	heart failure	Phase III www.janssen.com
INXN-4001 (gene therapy)	Precigen (Triple-Gene) Germantown, MD	heart failure	Phase I www.precigen.com
IONIS-AGT-LRX (RNA interference)	Ionis Pharmaceuticals Carlsbad, CA	chronic heart failure with reduced ejection fraction	Phase II www.ionispharma.com
JK07 (recombinant fusion protein)	SalubrisBio Gaithersburg, MD	heart failure	Phase I www.salubrisbio.com
Jardiance [®] empagliflozin	Boehringer Ingelheim Ridgefield, CT Lilly Indianapolis, IN	heart failure with reduced ejection fraction (Fast Track)	application submitted www.boehringer-ingelheim.com www.lilly.com
		heart failure with preserved ejection fraction (Fast Track)	Phase III www.boehringer-ingelheim.com www.lilly.com

Heart Failure

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
KBP-5074 (mineralocorticoid receptor antagonist)	KBP Biosciences Princeton, NJ	heart failure	Phase II www.kbpbio.com
lenrispodun (ITI-214) (PDE1 inhibitor)	Intra-Cellular Therapies New York, NY	heart failure	Phase I/II www.intracellulartherapies.com
LY3461767 (NRG4 agonist)	Lilly Indianapolis, IN	chronic heart failure	Phase I www.lilly.com
NAN-101 (vector-enabled gene therapy)	Asklepios BioPharmaceutical Research Triangle Park, NC	heart failure (NYHA class III)	Phase I www.askbio.com
omecamtiv mecarbil (cardiac myosin activator)	Amgen Thousand Oaks, CA Cytokinetics South San Francisco, CA	heart failure (Fast Track)	Phase III www.amgen.com www.cytokinetics.com
		pediatric heart failure	Phase I www.amgen.com www.cytokinetics.com
Opsumit® macitentan	Janssen Research & Development Raritan, NJ	heart failure with preserved ejection fraction	Phase II www.janssen.com
pecavaptan (dual vasopressin receptor antagonist)	Bayer Pharmaceuticals Whippany, NJ	heart failure	Phase II www.bayer.pharma.com
PL-3994 (cyclic natriuretic peptide receptor A agonist)	Palatin Technologies Cranbury, NJ	heart failure	Phase II www.palatin.com

Heart Failure
Drug Name

Sponsor

Indication

Development Phase

REGN5381
(NPR1 agonist antibody)

Regeneron
Tarrytown, NY

heart failure

Phase I
www.regeneron.com

Relaxin-LA

Lilly
Indianapolis, IN

heart failure

Phase I
www.lilly.com

Revascor®
rexlemestrocel
ORPHAN DRUG

Mesoblast
New York, NY

advanced heart failure

Phase III
www.mesoblast.com

end-stage ischemic heart failure

Phase I/II
www.mesoblast.com

ROMK inhibitor

Bristol-Myers Squibb
Princeton, NJ

heart failure

Phase I
www.bms.com

RT-100
(AC6 gene transference)

Renova Therapeutics
Carlsbad, CA

heart failure (Fast Track)

Phase II
www.renovatherapeutics.com

RT-400
(CRFR2 selective agonist)

Renova Therapeutics
Carlsbad, CA

acute decompensated heart failure

Phase II
www.renovatherapeutics.com

SOAANZ
(torsemide)

Sarfez Pharmaceuticals
Vienna, VA

heart failure

application submitted
www.sarfez.com

sotagliflozin
(oral SGLT1/2 inhibitor)

Lexicon Pharmaceuticals
The Woodlands, TX

heart failure

Phase III
www.lexpharma.com

Heart Failure

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
tirzepatide (GIP/GLP-1 dual receptor agonist)	Lilly Indianapolis, IN	heart failure with preserved ejection fraction	Phase III www.lilly.com
TT-00920 (PDE9 inhibitor)	TransThera Biosciences Nanjing, China	heart failure	Phase I
verinurad (SLC22A12 protein inhibitor)	AstraZeneca Wilmington, DE	heart failure with preserved ejection fraction	Phase II www.astrazeneca.com

HIV Infection

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
ABBV-181 (budigalimab) (anti-PD1 mAb)	AbbVie North Chicago, IL	HIV-1 infection	Phase I www.abbvie.com
ABBV-382 (antiretroviral)	AbbVie North Chicago, IL	HIV-1 infection	Phase I www.abbvie.com
AGT103-T (gene and cell therapy)	American Gene Technologies Rockville, MD	HIV infection (HIV cure)	Phase I www.americangene.com
albuvirtide (HIV fusion inhibitor)	Frontier Biotechnologies Nanjing, China	multi-drug resistant HIV-1 Infection (in combination with 3BNC117)	Phase II www.frontierbiotech.com
Anktiva™ inbakicept (IL-15 agonist)	ImmunityBio Culver City, CA	HIV infection	Phase II www.immunitybio.com

HIV Infection <u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
APH-0812 (PKC modulator/HDAC inhibitor)	Aphios Woburn, MA	HIV latency (combination treatment)	Phase I www.aphios.com
BRII-732 (NRTI and NRTTI)	Brii Biosciences Durham, NC	HIV infection	Phase I www.briibio.com
BRII-778 (extended release NNRTI)	Brii Biosciences Durham, NC	HIV infection	Phase I www.briibio.com
cabotegravir LA (HIV integrase inhibitor [long-acting intramuscular injection])	ViiV Healthcare Research Triangle Park, NC	HIV infection (PrEP) (Breakthrough Therapy)	application submitted www.viivhealthcare.com
ceNK (allogeneic cytokine-induced memory-like natural killer cells)	ImmunityBio Culver City, CA	HIV infection	Phase I www.immunitybio.com
CPT31 (D-peptide HIV entry inhibitor)	Navigen Pharmaceuticals Salt Lake City, UT	HIV infection	Phase I
Dovato® dolutegravir/lamivudine	ViiV Healthcare Research Triangle Park, NC	HIV infection (newly-diagnosed and pediatric)	Phase III www.viivhealthcare.com
elsulfavirine (NNRTI)	Viriom San Diego, CA	HIV infection (PrEP and PEP) (sustained-release oral)	Phase I www.viriom.com

HIV Infection
Drug Name

Sponsor

Indication

Development Phase

GOVX-B11 (clade-B DNA HIV vaccine)	GeoVax Labs Smyrna, GA	HIV infection (prevention)	Phase II www.geovax.com
		HIV infection (treatment) (functional cure)	Phase I www.geovax.com
GS-1156 (unboosted protease inhibitor)	Gilead Sciences Foster City, CA	HIV infection (treatment)	Phase I www.gilead.com
GS-1703 (lefitolimod) (TLR-9 agonist)	Gilead Sciences Foster City, CA	HIV infection (HIV cure)	Phase II www.gilead.com
GS-5423/GS-2872 (bNAb combination)	Gilead Sciences Foster City, CA	HIV infection (HIV cure)	Phase II www.gilead.com
		HIV infection (+GS-6207)	Phase I www.gilead.com
GS-6207 (lenacapavir) (capsid inhibitor)	Gilead Sciences Foster City, CA	HIV infection treatment in heavily treatment experienced people living with HIV (Breakthrough Therapy)	Phase II/III www.gilead.com
		HIV infection treatment for virologically suppressed people living with HIV	Phase II www.gilead.com
GS-9620 (vesatolimod) (TLR-7 agonist)	Gilead Sciences Foster City, CA	HIV infection (HIV cure)	Phase II www.gilead.com

HIV Infection <u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
GS-9722 (elipovimab) (bNAb)	Gilead Sciences Foster City, CA	HIV infection (HIV cure)	Phase I www.gilead.com
GS-9883 (bictegravir long-acting) (HIV integrase inhibitor)	Gilead Sciences Foster City, CA	HIV infection (treatment)	Phase I www.gilead.com
GSK3640254 (HIV maturation inhibitor)	ViiV Healthcare Research Triangle Park, NC	HIV-1 infection (treatment)	Phase II www.viivhealthcare.com
GSK3739937 (HIV replication inhibitor)	ViiV Healthcare Research Triangle Park, NC	HIV-1 infection (treatment)	Phase II www.viivhealthcare.com
GSK3810109A (bNAb)	ViiV Healthcare Research Triangle Park, NC	HIV-1 infection (treatment)	Phase II www.viivhealthcare.com
HIV vaccine (VAC89220) (Ad26 Mos HIV trivalent vaccine)	Janssen Vaccines and Prevention Leiden, Netherlands	HIV infection (prevention)	Phase III www.janssen.com
HIV vaccine (Ad26 Mos4 HIV vaccine)	Janssen Vaccines and Prevention Leiden, Netherlands	HIV infections (prevention) (+clade C and mosaic gp140 HIV bivalent vaccine)	Phase III www.janssen.com
HIV-1 vaccine	GeneCure Biotechnologies Norcross, GA	HIV-1 infection (treatment)	Phase I/II www.genecure.com

HIV Infection

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Ieronlimab (CCR5 antagonist)	Cytodyn Vancouver, WA	HIV infection (combination treatment) (Fast Track)	application submitted www.cytodyn.com
		HIV infection (monotherapy)	Phase II www.cytodyn.com
MGD014 (viral RNA inhibitor)	MacroGenics Rockville, MD	HIV -1 infection	Phase I www.macogenics.com
MB66 microbicide (monoclonal antibodies)	Mapp Biopharmaceutical San Diego, CA	HIV infection (prevention)	Phase I www.mappbio.com
MK-8558 (antiretroviral)	Merck Kenilworth, NJ	HIV infection	Phase I completed www.merck.com
MK-8591 (islatravir) (NRTTI)	Merck Kenilworth, NJ	HIV-1 infection (PrEP)	Phase III www.merck.com
MK-8591A (doravirine/islatravir)	Merck Kenilworth, NJ	HIV infection	Phase III www.merck.com
MK-8591B (islatravir/MK-8507)	Merck Kenilworth, NJ	HIV infection	Phase II www.merck.com
PENNVAX-GP (Gag, pol, env antigen vaccine)	Inovio Pharmaceuticals Plymouth Meeting, PA	HIV infection (prevention and treatment)	Phase II www.inovio.com

HIV Infection <u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
Pifeltro™ doravirine	Merck Kenilworth, NJ	HIV-1 infection (pediatric)	Phase II www.merck.com
Remune® GP120-depleted HIV-1 vaccine ORPHAN DRUG	Immune Response BioPharma Atlantic City, NJ	HIV-1 infection (adult and pediatric treatment)	application submitted www.immuneresponsebio.com
S-648414 (antiretroviral therapy)	Shionogi Florham Park, NJ	HIV infection	Phase II www.shionogi.com
SAR441236 (tri-specific neutralizing mAb)	Sanofi Bridgewater, NJ	HIV infections	Phase I www.sanofi.com
StealthVector® HGTV43™ (antisense HIV-1 therapy)	Enzo Therapeutics New York, NY	HIV-1 infection (treatment)	Phase II www.enzo.com
TMB-365 (anti-CD4 mAb)	TaiMed Biologics Taipei City, Taiwan	HIV infection (treatment & prevention)	Phase I www.taimedbiologics.com
Trogarzo™ ibalizumab intravenous push	US TaiMed Biologics Irvine, CA	HIV-1 infection (treatment)	Phase III www.taimedbiologics.com
VH3739937 (HIV maturation inhibitor)	ViiV Healthcare Research Triangle Park, NC	HIV infection	Phase I www.viivhealthcare.com
VH3810109 (HIV attachment inhibitor)	ViiV Healthcare Research Triangle Park, NC	HIV infection	Phase I www.viivhealthcare.com

HIV Infection

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Phase</u>
VIR-1111 (T cell vaccine)	Vir Biotechnology San Francisco, CA	HIV infection	Phase I www.vir.bio
VM1500A (NNRTI)	Viriom San Diego, CA	HIV infection (PrEP and PEP) (long-acting injectable)	Phase I www.viriom.com

Hypertension

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
ALN-AGT (RNA interference)	Alnylam Pharmaceuticals Cambridge, MA	hypertension	Phase I www.alnylam.com
aprocitantan (dual endothelin receptor antagonist)	Idorsia Pharmaceuticals Allschwil, Switzerland Janssen Biotech Horsham, PA	difficult to treat hypertension	Phase III www.adorsia.com www.janssen.com
B244 (bacteria-based therapeutic)	AOBiome Cambridge, MA	hypertension	Phase II www.aobiome.com
CIN-107 (aldosterone synthase inhibitor)	CinCor Pharma Cincinnati, OH	treatment-resistant hypertension	Phase II www.cincor.com
Edarbi [®] azilsartan medoxomil	Arbor Pharmaceuticals Atlanta, GA	hypertension (pediatric)	Phase III completed www.arborpharma.com
ION904 (angiotensinogen)	Ionis Pharmaceuticals Carlsbad, CA	treatment-resistant hypertension	Phase I www.ionispharma.com

Hypertension
Drug Name

Sponsor

Indication

Development Status

IONIS-AGT-LRX (RNA interference)	Ionis Pharmaceuticals Carlsbad, CA	treatment-resistant hypertension	Phase II www.ionispharma.com
KBP-5074 (mineralocorticoid receptor antagonist)	KBP Biosciences Princeton, NJ	uncontrolled hypertension in chronic kidney disease	Phase II www.kbpbio.com
QGC001 (brain aminopeptidase A inhibitor)	Quantum Genomics Paris, France	hypertension	Phase II www.quantum-genomics.com
RMJH-111B (magnesium citrate using inverted micellar technology)	RMJ Holdings Ashburn, VA	hypertension	Phase I completed www.rmjholdings.com

Liver Disease
Drug Name

Sponsor

Indication

Development Status

A3907 (ASBT inhibitor)	Albireo Pharma Boston, MA	primary biliary cirrhosis, primary sclerosing cholangitis	Phase I www.albireopharma.com
ADPT02	Novartis East Hanover, NJ	non-alcoholic steatohepatitis (NASH) (combination therapy)	Phase II www.novatis.com
aldafermin (NGM282) (FGF19 analog)	NGM Biopharmaceuticals South San Francisco, CA	NASH	Phase II www.ngmbio.com
ALN-HSD (HSD17B13 RNAi)	Alnylam Pharmaceuticals Cambridge, MA Regeneron Tarrytown, NY	NASH	Phase I www.alnylam.com www.regeneron.com

Liver Disease

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
ALT-801 (GLP-1/Glucagon receptor co-agonist)	Altimune Gaithersburg, MD	NASH	Phase I www.altimmune.com
ALY688-SR (adiponectin receptor agonist)	Allysta Pharmaceuticals Bellevue, WA	NASH	Phase I www.allysta.com
AMG 609 (siRNA)	Amgen Thousand Oaks, CA	NASH	Phase I www.amgen.com
aramchol (stearoyl CoA desaturase inhibitor)	Galmed Research & Development Tel Aviv, Israel	non-alcoholic steatohepatitis (NASH)	Phase III www.galmedpharma.com
ARO-HSD (HSD17B13 RNAi)	Arrowhead Pharmaceuticals Pasadena, CA	NASH	Phase I www.arrowheadpharma.com
ASC41 (THR-beta agonist)	Gannex Pharma (Ascletis) Shanghai, China	NAFLD	Phase I www.gannexpharma.com
ASC42 (FXR agonist)	Gannex Pharma (Ascletis) Shanghai, China	NASH (Fast Track)	Phase I www.gannexpharma.com
AXA1125 (metabolism modulator)	Axcella Health Cambridge, MA	NASH with fibrosis	Phase II www.axcellahealth.com
AZD2693 (adiponutrin inhibitor)	AstraZeneca Wilmington, DE	NASH	Phase I www.astrazeneca.com

Liver Disease

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
belapectin (galectin 3 inhibitor)	Galectin Therapeutics Norcross, GA	NASH cirrhosis	Phase III www.galectintherapeutics.com
		NASH advanced fibrosis (Fast Track)	Phase II www.galectintherapeutics.com
BI 456906 (GLP-1/glucagon agonist)	Boehringer Ingelheim Ridgefield, CT	NASH	Phase II www.boehringer-ingelheim.com
BIO89-100 (FGF replacement)	89Bio San Francisco, CA	NASH	Phase II www.89bio.com
BLD-0409 (autotaxin inhibitor)	Blade Therapeutics South San Francisco, CA	NASH	Phase I www.blademed.com
BMS-963272	Bristol-Myers Squibb Princeton, NJ	NAFLD	Phase I www.bms.com
BOS-580 (FGF21)	Boston Pharmaceuticals Cambridge, MA	NASH	Phase II www.bostonpharmaceuticals.com
CB4211 (analog of MOTS-c)	CohBar Menlo Park, CA	NASH	Phase I www.cohbar.com
Cellgram™ autologous mesenchymal stem cell therapy	Pharmicell Seoul, South Korea	alcoholic liver cirrhosis	Phase I www.pharmicell.com

Liver Disease

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
cilofexor (GS-9674) (FXR agonist)	Gilead Sciences Foster City, CA	primary sclerosing cholangitis	Phase III www.gilead.com
cilofexor/firsocostat/semaglutide combination	Gilead Sciences Foster City, CA Novo Nordisk Plainsboro, NJ	NASH (Fast Track)	Phase II www.gilead.com www.novonordisk.com
cotadutide (MEDI0382) (GLP-1/glucagon receptor dual agonist)	AstraZeneca Wilmington, DE	NASH	Phase II www.astrazeneca.com
CRV431 (cyclophilin inhibitor)	Hepion Pharmaceuticals Edison, NJ	NASH	Phase I www.hepionpharma.com
CT-868 (GLP-1/GIP receptor modulator)	Carmot Therapeutics Berkeley, CA	NASH	Phase I www.carmot-therapeutics.us
danuglipron (PF-06882961)/ PF-06865571 combination (GLP-1R agonist/DGAT2 inhibitor)	Pfizer New York, NY	NASH with liver fibrosis	Phase I www.pfizer.com
DUR-928 (oral) (inflammation mediator/lipid modulator)	DURECT Cupertino, CA	NASH	Phase I www.durect.com
EDP-297 (FXR agonist)	Enanta Pharmaceuticals Watertown, MA	NASH	Phase I www.enanta.com

Liver Disease

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
EDP-305 (FXR agonist)	Enanta Pharmaceuticals Watertown, MA	NASH	Phase II www.enanta.com
efruxifermin (FGF21 agonist)	Akero Therapeutics South San Francisco, CA	NASH	Phase II www.akerotx.com
elafibranor (PPAR α / δ agonist) ORPHAN DRUG	Genfit Loos, France	primary biliary cirrhosis (Breakthrough Therapy)	Phase III www.genfit.com
EYP001 (FXR agonist)	ENYO Pharma Lyon, France	NASH	Phase II www.enyopharma.com
FIA586	Novartis East Hanover, NJ	NASH	Phase I www.novartis.com
GDD3898	Lipidio Pharmaceuticals San Diego, CA	NASH	Phase II www.lipidiopharma.com
HM15211 (monomeric peptide triple agonist)	Hanmi Pharmaceutical Seoul, South Korea	NASH (Fast Track)	Phase II www.hamnipharma.com
HPG1860 (FXR agonist)	Hepagene Shanghai, China	NASH	Phase I www.hepagene.com
HPN-01 (IKK-1/IKK-2 inhibitor)	Hepanova Gaithersburg, MD	NASH	Phase I www.hepanova.com

Liver Disease
Drug Name

Sponsor

Indication

Development Status

HTD1801 (lipid modulator) ORPHAN DRUG	HighTide Biopharma Rockville, MD	NAFLD/NASH (Fast Track), primary sclerosing cholangitis (Fast Track)	Phase II www.hightidetx.com
HU6	Rivus Pharmaceuticals Charlottesville, VA	NASH	Phase I
icosabutate (cholesterol ester transfer protein inhibitor)	NorthSea Therapeutics Amsterdam, The Netherlands	NASH	Phase II www.northseatherapeutics.com
ION224 (DGAT2) (RNA interference)	Ionis Pharmaceuticals Carlsbad, CA	NASH	Phase I www.ioniapharma.com
JNK inhibitor (CC-90001)	Bristol-Myers Squibb Princeton, NJ	NASH with fibrosis	Phase II www.bms.com
KHK inhibitor	Lilly Indianapolis, IN	NASH	Phase I www.lilly.com
KHK inhibitor II	Lilly Indianapolis, IN	NASH	Phase I www.lilly.com
Ianifibranor (PPAR modulator)	Inventiva Pharma Daix, France	NASH (Breakthrough Therapy) (Fast Track)	Phase II www.inventivapharma.com
leronlimab (CCR5 antagonist)	CytoDyn Vancouver, WA	NASH	Phase I www.cytodyn.com

Liver Disease

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
LJN452 (tropifeor/licogliflozin) (FXR agonist/SGLT1-2 inhibitor)	Novartis East Hanover, NJ	NASH (Fast Track)	Phase II www.novartis.com
LPCN1144 (bioidentical testosterone)	Lipocine Salt Lake City, UT	NASH	Phase II www.lipicine.com
LYS006 (LTA4 inhibitor)	Novartis East Hanover, NJ	NAFLD/NASH (monotherapy and combination therapy)	Phase II www.novartis.com
MET409 (FXR agonist)	Metacrine San Diego, CA	NASH (in combination with anti-diabetic treatment)	Phase II www.metacrine.com
		NASH (monotherapy) (Fast Track)	Phase I www.metacrine.com
MET642 (FXR agonist)	Metacrine San Diego, CA	NASH (monotherapy) (Fast Track)	Phase II www.metacrine.com
miricorilant (glucocorticoid receptor modulator/ mineralocorticoid receptor antagonist)	Corcept Therapeutics Menlo Park, CA	NASH	Phase II www.corcept.com
MK-3655 (KLB-FGFR1c)	Merck Whitehouse Station, NJ	NASH	Phase II www.merck.com
MN-001 (tipelukast)	MediciNova La Jolla, CA	NAFLD/NASH (Fast Track)	Phase II www.medicinova.com

Liver Disease <u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
MNK-6105 (ammonia scavenger)	Mallinckrodt St. Louis, MO	hepatic encephalopathy in liver cirrhosis	Phase II www.mallinckrodt.com
MSDC-0602 (mitochondrial membrane transport protein modulator)	Cirius Therapeutics San Diego, CA	NAFLD/NASH	Phase II www.ciriustx.com
MT2004 (FXR agonist)	Biocare Pharma Xi'an, China	NASH	Phase I
NGM395 (GDF 15)	NGM Biopharmaceuticals South San Francisco, CA	NASH	Phase I www.ngmbio.com
nitazoxanide (receptor protein-tyrosine kinase modulator)	Genfit Loos, France	NASH-associated fibrosis	Phase II www.genfit.com
NN9499 (FGF21)	Novo Nordisk Plainsboro, NJ	NASH	Phase I www.novonordisk.com
OCA (obeticholic acid)	Intercept Pharmaceuticals New York, NY	fibrosis due to NASH	application submitted www.interceptpharma.com
		compensated cirrhosis due to NASH	Phase III www.interceptpharma.com
ORMD-0801 (oral insulin)	Oramed Pharmaceuticals New York, NY	NASH in patients with type 2 diabetes	Phase II www.oramed.com

Liver Disease

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
pegbelfermin (BMS-986036) (FGF-21 therapeutic)	Bristol-Myers Squibb Princeton, NJ	NASH	Phase II www.bms.com
PF-05221304+PF-068675571 (ACC inhibitor/DGAT2 inhibitor)	Pfizer New York, NY	NASH with liver fibrosis	Phase II www.pfizer.com
PF-06835919 (KHK inhibitor)	Pfizer New York, NY	NASH with liver fibrosis	Phase II www.pfizer.com
PF-06865571 (ervogastat) (DGAT2 inhibitor)	Pfizer New York, NY	NASH with liver fibrosis	Phase II www.pfizer.com
PLN-1474 (integrin alphav-beta1 inhibitor)	Novartis East Hanover, NJ Pliant Therapeutics South San Francisco, CA	NASH-associated liver fibrosis	Phase I www.novartis.com www.pliantrx.com
PXL065 (MPC inhibitor)	Poxel Lyon, France	NASH	Phase II www.poxelpharma.com
PXL770 (AMPK activator)	Poxel Lyon, France	NASH	Phase II www.poxelpharma.com
resmetirom (MGL-3196) (THR-beta agonist)	Madrigal Pharmaceuticals West Conshohocken, PA	NASH (Fast Track), NAFLD	Phase III www.madrigalpharma.com
RG7992 (BFKB8488A) (anti-FGFR1/KLB mAb)	Roche/Genentech South San Francisco, CA	NASH	Phase II www.gene.com

Liver Disease

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
saroglitazar (PPAR α / γ agonist) ORPHAN DRUG	Zydu-Cadila Ahmedabad, India	biliary cirrhosis (Fast Track)	Phase II www.zyducadila.com
seladelpar (PPAR-delta agonist) ORPHAN DRUG	CymaBay Therapeutics Newark, CA	primary biliary cirrhosis (Breakthrough Therapy)	Phase III www.cymabay.com
		NASH	Phase II www.cymabay.com
		primary sclerosing cholangitis	Phase I www.cymabay.com
semaglutide subcutaneous (GLP-1 agonist)	Novo Nordisk Plainsboro, NJ	NASH	Phase III www.novonordisk.com
SRT-015 (ASK1 inhibitor)	Seal Rock Therapeutics Seattle, WA	NASH	Phase I www.sealrocktx.com
T3D-959 (PPAR-delta/gamma agonist)	T3D Therapeutics Research Triangle Park, NC	NASH/NAFLD	Phase I www.t3dtherapeutics.com
TERN-101 (FXR agonist)	Terns Pharmaceuticals Foster City, CA	NASH (Fast Track)	Phase II www.ternpharma.com
TERN-201 (VAP-1 inhibitor)	Terns Pharmaceuticals Foster City, CA	NASH (Fast Track)	Phase I www.ternpharma.com

Liver Disease

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
TERN-501 (THR-beta agonist)	Terns Pharmaceuticals Foster City, CA	NASH	Phase I www.ternpharma.com
tirzepatide (GIP/GLP-1 dual receptor agonist)	Lilly Indianapolis, IN	NASH	Phase II www.lilly.com
TT-01025 (SSAO/VAP-1 Inhibitor)	LG Chem Seoul, South Korea TransThera Biosciences Nanjing, China	NASH	Phase I www.lgchem.com
TVB-2640 (FASN inhibitor)	Sagimet Biosciences San Mateo, CA	NASH (Fast Track)	Phase II www.sagimet.com
VK2809 (TRb agonist)	Viking Therapeutics San Diego, CA	NASH	Phase II www.vikingtherapeutics.com

Obesity

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
10XB-101 (polidocanol)	10xBio San Diego, CA	obesity	Phase II www.10xbio.com
AM833 (NN9838) (amylin receptor agonist)	Novo Nordisk Plainsboro, NJ	obesity	Phase II www.novonordisk.com
AM833-semaglutide 2.4 mg (amylin receptor agonist/GLP-1)	Novo Nordisk Plainsboro, NJ	obesity	Phase I www.novonordisk.com

Obesity Drug Name	Sponsor	Indication	Development Status
AMG 133 (GIPR antagonist/GLP-1 agonist)	Amgen Thousand Oaks, CA	obesity	Phase I www.amgen.com
AMG 171 (GDF15 analog)	Amgen Thousand Oaks, CA	obesity	Phase I www.amgen.com
BI 456906 (GLP-1/glucagon agonist)	Boehringer Ingelheim Ridgefield, CT	obesity	Phase II www.boehringer-ingelheim.com
BI 1356225	Boehringer Ingelheim Ridgefield, CT	obesity	Phase I www.boehringer-ingelheim.com
CB4211 (analog of MOTS-c)	CohBar Menlo Park, CA	obesity	Phase I www.cohbar.com
cotadutide (MEDI0382) (GLP-1/glucagon receptor dual agonist)	AstraZeneca Wilmington, DE	obesity	Phase II www.astrazeneca.com
CT-388 (GIP/GLP-1 receptor modulator)	Carmot Therapeutics Berkeley, CA	obesity	Phase I www.carmot-therapeutics.us
CT-868 (GIP/GLP-1 receptor modulator)	Carmot Therapeutics Berkeley, CA	obesity	Phase I www.carmot-therapeutics.us
danuglipron (PF-06882961) (GLP-1R agonist)	Pfizer New York, NY	obesity	Phase II www.pfizer.com

Obesity Drug Name	Sponsor	Indication	Development Status
DD01 (GLP-1R/GCGR dual agonist)	D&D Pharmatech/Neuraly Gaithersburg, MD	severe obesity in type 2 diabetes and NASH	Phase I www.ddpharmatech.com
ERX1000 (leptin sensitizer)	ERX Pharmaceuticals Cambridge, MA	obesity	Phase I www.erxpharmaceuticals.com
HDV (oral) (hepatic-directed vesicles)	Diasome Pharmaceuticals Cleveland, OH	obesity	Phase II www.diasome.com
HM15136 (glucagon receptor agonist)	Hanmi Pharmaceutical Songpa-gu, Seoul, Korea	obesity with comorbidities	Phase I www.hamnipharm.com
LA-GDF15 (NN9215) (growth differentiation factor replacement)	Novo Nordisk Plainsboro, NJ	obesity	Phase I www.novonordisk.com
MBL949	Novartis East Hanover, NJ	obesity related diseases	Phase I www.novartis.com
NGM395 (GDF 15)	NGM Biopharmaceuticals South San Francisco, CA	obesity	Phase I www.ngmbio.com
NO-13065	Otsuka Rockville, MD	obesity	Phase I www.otsuka.com
OPK88003 (pegapamidultide)	OPKO Health Miami, FL	obesity	Phase II www.opko.com

Obesity <u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
Ozempic® semaglutide injection 2.4 mg	Novo Nordisk Plainsboro, NJ	obesity	application submitted www.novonordisk.com
PF-07081532 (GLP-1R agonist)	Pfizer New York, NY	obesity	Phase I www.pfizer.com
PYY 1875 (peptide YY gut hormone)	Novo Nordisk Plainsboro, NJ	obesity	Phase I www.novonordisk.com
RZL-012 (lipolysis modulator) ORPHAN DRUG	Raziel Therapeutics Rehovot, Israel	obesity disorders	Phase II www.raziel-therapy.com
Saxenda® liraglutide	Novo Nordisk Plainsboro, NJ	obesity (6-12 years)	Phase III www.novonordisk.com
tirzepatide (GIP/GLP-1 dual receptor agonist)	Lilly Indianapolis, IN	obesity	Phase III www.lilly.com
Xla1 (Christensenella minuta oral biotherapy)	YSOPIA Bioscience Cedex, France	obesity	Phase I www.ysopia.bio

Sickle Cell Disease Drug Name

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
Adakveo® crizanlizumab	Novartis East Hanover, NJ	prevention of vaso-occlusive crises in sickle cell disease (6 months-7 years)per	Phase II www.novartis.com

Sickle Cell Disease

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
ADPT03 (BCL-11A)	Novartis East Hanover, NJ	sickle cell disease	Phase I www.novatis.com
AG-946 (PKR activator)	Agios Pharmaceuticals Cambridge, MA	sickle cell disease	Phase I www.agios.com
ARU-1801 (lentiviral gene therapy) ORPHAN DRUG	Aruvant Sciences New York, NY	sickle cell disease	Phase II www.aruvant.com
BCL11a shRNA(miR) (RNA interference)	bluebird bio Cambridge, MA	severe sickle cell disease	Phase I www.bluebirdbio.com
CSL200 CAL-H (γ-globin gene therapy)	CSL Behring King of Prussia, PA	sickle cell disease	Phase II www.cslbehring.com
CSL889 (hemopexin) (hemopexin replacement) ORPHAN DRUG	CSL Behring King of Prussia, PA	sickle cell disease	Phase I www.cslbehring.com
CTX001 (autologous gene-edited hematopoietic stem cell therapy) ORPHAN DRUG	CRISPR Therapeutics Cambridge, MA Vertex Pharmaceuticals Boston, MA	sickle cell disease (Fast Track)	Phase I/II www.crisprtx.com www.vrtx.com
EDIT-301 (ex vivo gene edited stem cell therapy)	Editas Medicine Cambridge, MA	sickle cell disease	Phase I/II www.editasmedicine.com

Sickle Cell Disease

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
EPI01 (decitabine/tetrahydrouridine) ORPHAN DRUG	Novo Nordisk Princeton, NJ	sickle cell disease (Fast Track)	Phase I www.novonordisk.com
FT-4202 (PKR activator) ORPHAN DRUG	FORMA Therapeutics Watertown, MA	sickle cell disease (Fast Track)	Phase II/III www.formatherapeutics.com
FTX-6058 (EED inhibitor)	Fulcrum Therapeutics Cambridge, MA	sickle cell disease	Phase I www.fulcrumtx.com
GBT-021601 (HbS polymerization inhibitor)	Global Blood Therapeutics South San Francisco, CA	sickle cell disease	Phase I www.gbt.com
HIX763 (genome-edited, autologous, hematopoietic stem cell therapy)	Novartis East Hanover, NJ	sickle cell disease (monotherapy and combination therapy)	Phase I/II www.novartis.com
IMR-687 (tivinontrine) (PDE9 inhibitor) ORPHAN DRUG	Imara Cambridge, MA	sickle cell disease (Fast Track)	Phase II www.imaratx.com
inclacumab (P selectin inhibitor)	Global Blood Therapeutics South San Francisco, CA	vaso-occlusive crisis in sickle cell disease	Phase I www.gbt.com
intravenous citrulline (amino acid replacement)	Asklepion Pharmaceuticals Baltimore, MD	acute sickle cell crisis	Phase I www.asklepionpharm.com

Sickle Cell Disease

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
KDFX (deferasirox)	Austhena BioSciences Georgetown, TX	iron overload in sickle cell disease	Phase II www.austherabio.com
LentiGlobin® beta-globin gene therapy ORPHAN DRUG	bluebird bio Cambridge, MA	severe sickle cell disease (Fast Track)	Phase III www.bluebirdbio.com
		severe sickle cell disease	Phase I/II www.bluebirdbio.com
mitapivat (PKR activator) ORPHAN DRUG	Agiros Pharmaceuticals Cambridge, MA	sickle cell disease (adults)	Phase II/III www.agios.com
		sickle cell disease (pediatric)	Phase I www.agios.com
olinciguat (IW-1701) (sGC agonist) ORPHAN DRUG	Cyclerion Therapeutics Cambridge, MA	sickle cell disease	Phase II www.cyclerion.com
OTQ923 (genome-edited hematopoietic stem and progenitor cell therapy)	Novartis East Hanover, NJ	sickle cell disease (monotherapy and combination therapy)	Phase I/II www.novartis.com
Oxbryta® voxelotor (GBT440) (sickle hemoglobin modulator)	Global Blood Therapeutics South San Francisco, CA	sickle cell disease (9 months-17 years)	Phase I/II www.gbt.com

Sickle Cell Disease

<u>Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
PB-04 (benserazide) (suppressing fetal globin gene promoter)	Phoenicia Biosciences Weston, MA	sickle cell disease	Phase I/II www.phbiosci.com
PF-07059013 (hemoglobin beta modulator) ORPHAN DRUG	Pfizer New York, NY	sickle cell disease	Phase I www.pfizer.com
PF-07209326 (E-selectin antagonist) ORPHAN DRUG	Pfizer New York, NY	sickle cell disease	Phase I www.pfizer.com
Sanguinate® PEGylated hemoglobin and carbon monoxide ORPHAN DRUG	Prolong Pharmaceuticals South Plainfield, NJ	vaso-occlusive crises in sickle cell disease	Phase II www.prolongpharma.com
SAR445136 (ZFN gene-edited cell therapy) ORPHAN DRUG	Sangamo Therapeutics Richmond, CA Sanofi Bridgewater, NJ	sickle cell disease (Fast Track)	Phase I www.sangamo.com www.sanofi.com
SC411 (docosahexaenoic acid) ORPHAN DRUG	Micelle BioPharma Riviera Beach, FL	sickle cell disease	Phase II www.micellebiopharma.com

Stroke Drug Name	Sponsor	Indication	Development Status
3K3A-APC (recombinant human wild-type activated protein C)	ZZ Biotech Houston, TX	acute ischemic stroke (Fast Track)	Phase II www.zzbiotech.com
abelacimab (MAA868) (anti-FXI mAb)	Anthos Therapeutics Cambridge, MA	stroke prevention in atrial fibrillation	Phase II www.anthostherapeutics.com
asundexian (FXIa inhibitor)	Bayer Pharmaceutical Whippany, NJ	stroke prevention in atrial fibrillation, 2nd stroke prevention	Phase II www.pharma.bayer.com
BIIB093 (glibenclamide IV) (SUR1-TRPM4 channel inhibitor) ORPHAN DRUG	Biogen Cambridge, MA	large hemispheric infarction (severe form of ischemic stroke) (Fast Track)	Phase III www.biogen.com
clazosentan (endothelin receptor antagonist) ORPHAN DRUG	Idorsia Pharmaceuticals Allschwil, Switzerland	cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage	Phase III www.idorsia.com
CTX0E03 (neural stem cell therapy)	ReNeuron Bridgend, United Kingdom	ischemic stroke	Phase II www.reneuron.com
DM199 (recombinant human kallikrein-1)	DiaMedica Therapeutics Minneapolis, MN	acute ischemic stroke	Phase II www.diamedica.com
elezanumab (ABT-555) (RGMa protein inhibitor)	AbbVie North Chicago, IL	acute ischemic stroke	Phase II www.abbvie.com
LT3001 (antioxidant/free radical scavenger)	Lumosa Therapeutics Taipei, Taiwan	acute ischemic stroke	Phase I www.lumosa.com.tw

Stroke Drug Name	Sponsor	Indication	Development Status
mesenchymal stem cell therapy (ischemic-tolerant stem cells)	Stemedica Cell Technologies San Diego, CA	ischemic stroke	Phase II www.stemedica.com
milvexian (BMS-986177/JNJ-70033093) (factor X _{II} a inhibitor)	Bristol-Myers Squibb Princeton, NJ Janssen Research & Development Raritan, NJ	prevention of stroke	Phase II www.bms.com www.janssen.com
MultiStem [®] invimestrocel	Athersys Cleveland, OH	ischemic stroke (Fast Track)	Phase III www.athersys.com
NCS-01 (mesenchymal stem cell therapy)	NC Medical Research Tokyo, Japan	stroke	Phase I/II www.ncmr.co.jp
Nan02 (dodecafluoropentane nanoemulsion)	NuvOx Pharma Tucson, AZ	acute ischemic stroke	Phase I/II completed www.nuvoxpharma.com
PMZ-1620 (sovateltide) (endothelin-B receptor agonist)	Pharmazz Willowbrook, IL	acute ischemic stroke	Phase III www.pharmazz.com
RGN-352 injectable (thymosin beta-4)	RegeneRx Biopharmaceuticals Rockville, MD	stroke	Phase I completed www.regenerx.com
Sanguinate [®] PEGylated carboxyhemoglobin bovine (PP-007)	Prolong Pharmaceuticals South Plainfield, NJ	acute ischemic stroke	Phase I www.prolongpharma.com

<u>Stroke Drug Name</u>	<u>Sponsor</u>	<u>Indication</u>	<u>Development Status</u>
SB623 (modified bone marrow derived mesenchymal stem cells)	SanBio Mountain View, CA	ischemic stroke	Phase II www.sanbio.com
TF0023 (aspirin pro-drug)	Techfields Pharma Dover, DE	ischemic stroke	Phase II www.tfpharma.com
TMS-007 (plasminogenmodulator)	Biogen Cambridge, MA	acute ischemic stroke	Phase I www.biogen.com
TNKase® tenecteplase	Roche/Genentech South San Francisco, CA	late-window acute ischemic stroke (between 4.5 and 24 hours)	Phase III www.roche.com
TSO1 (mutant pro-urokinase)	Thrombolytic Science International Cambridge, MA	ischemic stroke	Phase II www.tsillc.com
Y-2 (edaravone and borneol)	YenePharma Jiangsu, China	acute stroke	Phase I www.yenepharma.com

The content of this report has been obtained through public, government and industry sources, and the Springer "Adis Insight" database based on the latest information. **Report current as of June 8, 2021.** The medicines in this listing include medicines being developed by U.S.-based companies conducting trials in the United States and abroad, PhRMA-member companies conducting trials in the United States and abroad, and foreign companies conducting clinical trials in the United States. Some products may not be in active clinical trials. The information may not be comprehensive. For more, specific information about a particular product, contact the individual company directly or go to www.clinicaltrials.gov. The entire series of *Medicines in Development* is available on PhRMA's website: www.phrma.org.

Definitions

Application Submitted—An application for marketing has been submitted by the company to the U.S. Food and Drug Administration (FDA).

Breakthrough Therapy—Upon request by a sponsor, the FDA can grant this designation to expedite the development and review of a drug or biologic intended, alone or in combination with one or more other drugs, to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically-significant endpoints, such as substantial treatment effects observed early in clinical development. If a drug or biologic is designated as a Breakthrough Therapy, the FDA will expedite the development and review. With this designation, all Fast Track features convey to the medicine.

Fast Track—Upon request by a sponsor, the FDA can grant this designation to facilitate the development and expedite the review of a drug or biologic to treat a serious condition and fill an unmet medical need. When considering a biopharmaceutical company's request for Fast Track designation for an investigational drug or biologic, the FDA evaluates whether it will affect factors such as survival, day-to-day functioning, or the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one, and whether a condition can be adequately addressed by available therapy. With Fast Track designation, early and frequent communication between the FDA and the biopharmaceutical company is encouraged throughout the entire drug development and review process to help to quickly resolve any questions or issues that arise, potentially leading to an earlier approval and access by patients.

Orphan Designation—Upon request by a sponsor, the FDA can grant special status (“orphan status”) to a drug or biologic to treat a rare disease or condition. In order to receive an orphan designation, a qualifying drug or biologic must be intended for the treatment, diagnosis, or prevention of a rare disease or condition that affects usually fewer than 200,000 people in the United States.

Phase I—Researchers test the investigational drug or biologic in a small group of people, usually between 20 and 100 healthy adult volunteers, to evaluate its initial safety and tolerability profile, determine a safe dosage range, and identify potential side effects.

Phase II—The investigational drug or biologic is given to volunteer patients, usually between 100 and 500, to determine whether it is effective, identify an optimal dose, and to further evaluate its short-term safety.

Phase III—The investigational drug or biologic is given to a larger, more diverse patient population, often involving between 1,000 and 5,000 patients (but sometimes many more), to generate statistically significant evidence to confirm its safety and effectiveness. Phase III studies are the longest studies and usually take place in multiple sites around the world.